

Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML

Received: 3 February 2023

Accepted: 20 May 2024

Published online: 04 June 2024

 Check for updates

Matteo Marchesini^{1,2,3}, Andrea Gherli^{1,2,14}, Elisa Simoncini^{1,2,14}, Lucas Moron Dalla Tor^{1,2,14}, Anna Montanaro^{1,2}, Natthakan Thongon⁴, Federica Vento^{2,5}, Chiara Liverani³, Elisa Cerretani^{2,5}, Anna D'Antuono^{1,2}, Luca Pagliaro^{1,2,6}, Raffaella Zamponi^{1,2}, Chiara Spadazzi³, Elena Follini⁷, Benedetta Cambò⁶, Mariateresa Giaimo^{1,2,6}, Angela Falco¹, Gabriella Sammarelli⁶, Giannalisa Todaro⁶, Sabrina Bonomini⁶, Valentina Adami⁸, Silvano Piazza^{8,9}, Claudia Corbo^{10,11}, Bruno Lorusso¹, Federica Mezzasoma¹², Costanza Anna Maria Lagrasta¹, Maria Paola Martelli¹², Roberta La Starza¹², Antonio Cuneo^{5,13}, Franco Aversa¹⁵, Cristina Mecucci¹², Federico Quaini¹, Simona Colla^{1,4} & Giovanni Roti^{1,2,6} ✉

The overexpression of the ecotropic viral integration site-1 gene (*EVII/MECOM*) marks the most lethal acute myeloid leukemia (AML) subgroup carrying chromosome 3q26 abnormalities. By taking advantage of the intersectionality of high-throughput cell-based and gene expression screens selective and pan-histone deacetylase inhibitors (HDACis) emerge as potent repressors of *EVII*. To understand the mechanism driving on-target anti-leukemia activity of this compound class, here we dissect the expression dynamics of the bone marrow leukemia cells of patients treated with HDACi and reconstitute the *EVII* chromatin-associated co-transcriptional complex merging on the role of proliferation-associated 2G4 (PA2G4) protein. *PA2G4* overexpression rescues AML cells from the inhibitory effects of HDACis, while genetic and small molecule inhibition of PA2G4 abrogates *EVII* in 3q26 AML cells, including in patient-derived leukemia xenografts. This study positions PA2G4 at the crosstalk of the *EVII* leukemogenic signal for developing new therapeutics and urges the use of HDACis-based combination therapies in patients with 3q26 AML.

In the last two decades, access to rapidly evolving molecular technologies has dramatically changed the treatment landscape for patients with acute leukemia. Although an increased understanding of the genomic underpinnings of hematopoietic malignancies has led to targeted approaches, especially for mutated kinases, little progress has been made in (i) highly aggressive and rare subgroups, (ii) relapsed and

refractory disease, and (iii) leukemia subtypes driven by aberrantly activated transcription factors (TFs).

While TFs have been considered “undruggable” for decades, emerging or improved approaches targeting the modulation of TF activity or expression levels, TF trafficking, and nucleus positioning, or accelerating TF degradation through proteolysis targeting chimeras

have repositioned this unique class of drug targets among the most desired cancer therapeutics^{1,2}. Several of these approaches showed promising preclinical activity, and a few have been translated into clinical applications or clinical trials, paving the way for transcriptional-based therapy in cancer.

The acute myeloid leukemia (AML) model that carries a 3q26 defect such as the *inv*(3)(q21;q26), *t*(3;3)(q21;q26), *ins*(3;3)(q26;q21;q26), *t*(3;8)(q26;q24), and *t*(3;21)(q26;q22) involving the TF Ecotropic Virus Integration *EVII* [*MDS and EVII* complex locus (*MECOM*)]³ in the 3q26 locus exemplifies aggressiveness, with the poorest overall survival (OS) and refractoriness against conventional chemotherapy^{4,5}.

While 3q26 AMLs have been identified as a distinct subgroup of AML^{4,6–9}, little has been done to improve their clinical outcome. Most patients with 3q26 abnormalities are misdiagnosed¹⁰ and treated with a cytarabine (ara-C) and anthracycline-based protocol¹¹, despite early evidence that they do not experience a response to cytotoxic drugs^{12,13} or myeloablative allogeneic hematopoietic stem cell (HSC) transplantation¹⁴. However, targeted repression of *EVII* based on small molecule, epigenetic, and metabolic approaches impairs leukemia progression in preclinical cancer models, suggesting that *EVII* represents a cancer dependency and a tumor biomarker for high-risk AML^{15–17}. While these approaches are promising, efforts to optimize *EVII* suppression for clinical translation are still underway.

Here, we identify a druggable mediator of HDACis response in 3q26 AML and mechanistically demonstrate evidence of targeted suppression of *EVII* using phenotypic and genome-based in silico small molecule screen approaches and a proteomic analysis of the *EVII* chromatin complex in preclinical-3q26-leukemia-models and leukemia patients.

Results

Identification of small molecules modulating *EVII*

We performed a phenotypic screen focusing on antiproliferative agents in parallel with a gene-expression-based screen approach to identify molecules that impair cell proliferation by suppressing an *EVII* signature (Fig. 1A) in AML cells overexpressing *EVII* (*EVII*^{High}). We screened 5292 drugs or drug-like small molecules, including natural derivative compounds in the human 3q26 *EVII*^{High} AML cell lines MOLM1 and UCSD/AML1 carrying the chromosome recombinations *inv*(3)(q21.3;q26.2) and *t*(3;3)(q21.3;q26.2), respectively (Supplementary Data 1). The effect of compound treatment was normally distributed, and the majority of the compounds did not impair cell viability (Supplementary Fig. 1A, B). Plate-specific spatial biases did not affect the experimental screening data (Supplementary Fig. 1C), except for differences due to cell lines. We scored compounds based on their ability to suppress proliferation compared to vehicle controls (Δ POC). We selected 228 (95th percentile) small molecules to pursue further based on Δ POC inhibition (Fig. 1B). Among top-scoring hits, with the potential for clinical translation, histone deacetylase inhibitors (HDACis), proteasome modulators, topoisomerase and protein kinase inhibitors reduced the growth of *EVII*^{High} AML by 90% (Fig. 1C). Of these, 40 small molecules with the highest Δ POC index ($>84\%$, $Adj.P \leq 2 \times 10^{-33}$) (Supplementary Data 1) were counter-screened in an additional *t*(3;3)(q21.3;q26.2) *EVII*^{High} AML cell line (HNT34) and two not-translocated (*EVII*^{Low}) AML cell lines, NOMO1 (*KRAS*^{G13D}) and THP1 (*NRAS*^{G12D}); these were selected because they carry mutations in the RAS signaling¹⁸ as in 3q26 AMLs. The HDACis AR-42, belinostat, trichostatin A, and entinostat preferentially affect the proliferation of *EVII*^{High} AML cells compared to *EVII*^{Low}, suggesting that *EVII* sensitizes 3q26 AML cells to HDACi-mediated cytotoxicity (Supplementary Fig. 1D).

We redefined an *EVII* transcriptional signature from genome-wide expression profiling of *EVII*^{High} AML (TF1) transduced with an siRNA targeting *EVII*¹⁹. We obtained a set of 1428 modulated genes ($P \leq 0.05$

by the two-sided Student's t-test) and selected the top 100 up- or down-regulated genes, ranked by the signal-to-noise ratio, to define an *EVII* “On” versus an “Off” state (Supplementary Fig. 2A). We then interrogated publicly available large-scale chemical and genetic perturbation datasets (<https://clue.io/cmap>)²⁰ to identify small molecules that mimic *EVII* transcriptional suppression. HDACis ranked on the top of the hit list were associated with the *EVII* “Off” status (Fig. 1D and Supplementary Data 1). Most (56.2%) of the HDACis sampled in the CMap libraries scored among the top 250 hits ($P = 0.0006$, Fig. 1E). However, because HDACis are overrepresented in small molecule libraries compared to other classes, we determined whether the size of the compound class ($n = 32$) interfered with our result. Compound classes with similar or higher representation, such as histamine ($n = 52$), glucocorticoid, ($n = 47$), or acetylcholine receptor antagonists ($n = 66$), did not show significant enrichment with an *EVII* “Off” status (Supplementary Fig. 2B). Consistently, a tertiary screen of 4942 small molecules confirmed the potent antiproliferative activity of HDACis compared to non *EVII* “Off” inducers (Supplementary Fig. 2C) in TF1 cells.

To validate data derived from the analysis of published datasets¹⁹, we downregulated *EVII* by shRNA in HNT34 cells and detected changes in RNA abundance with more than 2224 transcripts changing from $\log_2$ fold ≥ 2 (false discovery rate (FDR) ≤ 0.01) (Supplementary Fig. 2D). The overlap between *EVII*-regulated gene signatures in HNT34 and *EVII*-dependent genes in TF1 (Supplementary Fig. 2E) indicates their appropriateness for additional gene-expression-based in silico drug screening approaches. Projection of the HNT34 signature onto the LINCS L1000²¹ dataset space demonstrated that transcriptional changes associated with an *EVII* “Off” status mimic and match HDACis signatures (Fig. 1F, Supplementary Fig. 2F, G and Supplementary Data 1). The suppression of an *EVII*-transcriptional program due to HDAC perturbation was also replicated in a separate dataset derived from AML cell lines distinguished based on their 3q26 status (Fig. 1F, Supplementary Fig. 2F, G and Supplementary Data 1)¹⁵.

Taken together, these data suggest that HDACis inhibit 3q26 AML cell proliferation and modulate *EVII*, supporting their investigation as a targeted approach in 3q26 AMLs.


HDACis suppress 3q26 AML growth

To set conditions for validating our results, we confirmed the expression of *EVII* and Δ *EVII* protein isoforms²² in the 3q26 *EVII*^{High} AML cell lines (Fig. 2A, B) and demonstrated the dependency of these cells on *EVII* expression (Fig. 2C–E, Supplementary Fig. 3A–C). Suppression of *EVII* abrogates the growth and the clonogenic capacity of *EVII*^{High} AML (Fig. 2E, F and Supplementary Fig. 3C, D).

We then selected a panel of molecules with pan (AR-42, belinostat) or selective (entinostat, class 1/2) HDAC inhibitory activity based on their potential in clinical translation in high-risk-AML. AR-42 (Δ POC = 99.54; $Adj.P = 1.51 \times 10^{-34}$) has been investigated in clinical trials for the treatment of hematologic malignancies (e.g. NCT01129193 and NCT02569320); belinostat (also known as PXD101, Δ POC = 98.14; $Adj.P = 1.51 \times 10^{-34}$) has been approved for cutaneous of T-cell lymphoma²³; and entinostat (Δ POC = 87.43; $Adj.P = 7.55 \times 10^{-34}$) has been tested in myeloid malignancies, irrespective of the genetic status (e.g. NCT00313586 and NCT01159301)²⁴. All molecules displayed half-maximal inhibitory concentrations (IC_{50}) within the low micromolar range: AR-42 from 0.221 μ M to 0.438 μ M (0.329 ± 0.153), belinostat from 0.379 μ M to 0.951 μ M (0.665 ± 0.404), and entinostat from 0.812 μ M to 1.686 μ M (1.249 ± 0.618) (Fig. 2G). Treatment with HDACis also induced a dose-dependent increase in apoptosis (Fig. 2H, I and Supplementary Fig. 3E, F), and suppressed blast colony formation (Fig. 2J, K).

EVII sensitizes 3q26 AML to HDAC-mediated suppression

To test whether the effects of HDACis were due to *EVII* suppression, we treated *EVII*^{High} AML cell lines with AR-42, belinostat, and entinostat



and observed a loss of *EV1* both at transcriptional and protein level. In contrast, cleaved caspase 3 was regulated in the opposite direction, consistent with the apoptosis data presented above (Fig. 3A, B and Supplementary Fig. 4A).

To further assess whether *EV1* sensitizes AML cells to HDAC inhibition, we leveraged an *EV1*-inducible leukemia model²⁵. U937T cells that conditionally expressed the full-length isoform of *EV1*

under the control of the tetracycline promoter were grown in the presence (*EV1* "Off") or absence of tetracycline (*EV1* "On"). *EV1* expression was observed 24 hr after tetracycline removal (Fig. 3C and Supplementary Fig. 4B). U937T (E10 clone) were then treated with AR-42, belinostat, and entinostat in a 2-fold dilution series for three additional days. Despite a growth difference between U937T "On" or "Off" (Supplementary Fig. 4C), cells grown in the absence of

Fig. 1 | Identification of *EVII* modulators from the intersection of phenotypic and genome-based approaches. **A** Identification of *EVII* “Off” modulators by the integration of phenotypic and in silico gene-expression-based screen approaches. **B** Circos plot summarizing primary small molecule screening in *EVII*^{High} AML cell lines. The heatmap at the external circle shows the normalized percentage of cell death (Δ POC) for the 95th percentile for the compounds tested. The middle circos shows the compound libraries: i) Spectrum Collection ($n = 1914$); ii) the anti-cancer compound library ($n = 343$); and iii) the NDL-3000 library ($n = 3035$). The inner plot shows a hierarchical cluster of top candidates’ scalar fingerprints (SMILE), based on the Tanimoto similarity metric. **C** Dot plot showing the effects of the compound tested ($n = 5292$), ranked based on Δ POC. The yellow area indicates the 95th percentile. HDAC inhibitors (HDACis) are labeled in red. **D** Rank-score log-scale plots for HDACis ($n = 32$), histamine ($n = 52$), glucocorticoid ($n = 47$), and acetylcholine

receptor antagonists ($n = 66$). In black, the number of perturbagenes inferred in the connectivity map of which 2836 are small molecules. Compounds of interest are color-coded and expressed as a percentage relative to the entire library. **E** Bar plot showing the HDACis (in red) ranking in the ConnectivityMap²⁰ dataset. The tau score represents the level of similarity to the *EVII* “On” or “Off” status. **F** L1000FWD fireworks visualization of drug-induced signatures mimicking and reversing the differential gene expression signature generated from *EVII*-silenced HNT34 (left) and from *EVII*^{High} ($n = 5$) or *EVII*^{Low} ($n = 2$) AML cell lines contained in the E-MTAB-2225 dataset (right). Aquamarine circles indicate small molecules causing a reverse signature *EVII* “Off”. Light violet circles indicate small molecules mimicking a signature *EVII* “On”. HDACis drug-induced signatures are indicated in green overlapping with aquamarine circles. See also Supplementary Fig. 1–2 and Supplementary Data 1.

tetracycline, with the highest *EVII* expression, were more sensitive to the effects of HDACis (Fig. 3D). *EVII*^{High} and *EVII*^{Low} U937T were equally sensitive to ara-C, suggesting that the expression of *EVII* preferentially enhances the HDACi-induced inhibition of cell viability compared to chemotherapy (Fig. 3D and Supplementary Fig. 4D). Similar results were obtained in a constitutive model of *EVII* expression in HL-60 cells (Fig. 3E, F and Supplementary Fig. 4E). We then sorted MOLM1 cells by size, distinguishing *EVII*-positive cells with large nuclei and prominent nucleoli, and *EVII*-negative cells, smaller in size with weak or no *EVII* protein expression (Figs. 2B and 3G, H). In this isogenic model HDACi were more active in MOLM1 *EVII*^{High} cells compared to MOLM1 *EVII*^{Low} (Fig. 3I). Consistently, *EVII*^{High} ($n = 5$) and *EVII*^{Low} ($n = 7$) AML cell lines were equally sensitive to other chemotherapy agents but not to AR-42, belinostat, and entinostat (Fig. 3J).

In addition, the interaction of 3q26 AML cells with a collagen substrate in a three-dimensional (3D) porous and cell-permeant culture system²⁶ (Supplementary Fig. 4F) used to mimic the bone marrow microenvironment did not rescue the cytotoxic effect of HDACis. Here, *EVII*^{High} cells aggregate in niche-like structures similar to AML clusters in the bone marrow stroma, retain *EVII* expression, and grow with a doubling time of ~6 days (Supplementary Fig. 4G–I). *EVII*^{High} cells cultured in biomimetic 3D collagen scaffolds develop resistance to ara-C but not to HDACis, suggesting that cell-extrinsic mechanisms of acquired resistance to chemotherapy agents can be overcome by targeting *EVII* in 3q26 AML (Supplementary Fig. 4J).

Collectively, these data demonstrate that *EVII* expression in 3q26 AML sensitizes cells to HDAC inhibition, providing a rationale for translating these molecules in clinical practice.

HDACis suppress *EVII* in patients with 3q26 AML

Since January 2017, we have admitted five patients to our hospital affected by AML carrying 3q26 abnormalities and collected six additional samples from different institutions (PR#001-009 and PR#023-024). Four out eleven patients had atypical 3q26 rearrangements (PR#001, PR#004, PR#005, and PR#024) (Supplementary Fig. 5A and Supplementary Data 2). Sequencing and cytogenetic analyses confirmed a high frequency of RAS mutations²⁷ (63.6% mutated in *KRAS* or *NRAS*) and monosomy of chromosome 7 (63.6%) compared to non-rearranged cases (PR#010-022 and PR#025-039) (Supplementary Fig. 5B and Supplementary Data 2). All patients carrying 3q26 abnormalities presented severe clinical conditions and experienced disease relapse after multiple lines of chemotherapy or HSCT (Supplementary Data 2). In primary AML blasts, suitable for ex vivo studies, AR-42, belinostat, and entinostat inhibited cell viability in 2D and 3D models (Fig. 4A, B and Supplementary Fig. 6A). 3q26 AML cells collected from clinical samples ($n = 9$) were more sensitive to HDAC suppression than were other AML subtypes ($n = 28$) and equally responsive to chemotherapy agents in vitro (Fig. 4C). For samples with adequate cells for additional tests, *EVII* expression was almost undetectable after 24 hr of HDACis treatment, consistent with the disappearance from the nucleus, and inversely correlated with the

increase of cleaved caspase 3 (Fig. 4D–F). Importantly, ara-C did not cause significant changes in *EVII* nuclear protein abundance (Fig. 4E, F and Supplementary Fig. 6B).


Three patients (PR#001, PR#002, and PR#003) were enrolled in a compassionate use program that tested azacitidine at 50 mg/m² (days 1–10) and entinostat 4 mg/m² (days 3 and 10), every 28 days. This schedule was approved in the NCT00101179 clinical trial for AML or myelodysplastic syndromes²⁸. Two patients received standard support or chemotherapy (PR#004 and PR#005); the remaining were treated in a different hospital. The mean survival duration of patients receiving an entinostat-based regimen was 20.3 months without significant organ toxicity compared to 4.5 months for those receiving standard of care (Supplementary Fig. 6C, D and Supplementary Data 2).

Leveraging previous studies describing the pharmacokinetics properties of entinostat²⁹, we also demonstrated that *EVII* protein levels markedly decrease in circulating AML blasts following 4 mg/m² of entinostat compared to ara-C both in treated patients (Fig. 4G) or in the matched 3q26 PDLX models (Supplementary Fig. 6E).

In summary, these data support the idea of testing HDACi-based combination therapy in patients with 3q26 AML in randomized clinical trials and suggest the use of *EVII* as a potential biomarker of response to epigenetic treatment or resistance to standard of care (Fig. 4H) in patients with *EVII*-dependent leukemia.

EVII inhibition modulates the Myc transcriptional program

We then hypothesized that the preferential activity of HDACis in 3q26 AML may be related to the impaired function of the *EVII* co-transcriptional complex. We profiled *EVII*^{High} AML cell lines after 16 hr of treatment with AR-42 (0.5 μ M and 1.0 μ M, respectively) and entinostat (2 μ M and 4 μ M, respectively) by mRNA and ChIP-Seq. Consistent with the role of HDAC in chromatin-dependent transcriptional regulation, there was a preponderance of up-regulated genes (1309) versus down-regulated genes (107) (Supplementary Fig. 7A and Supplementary Data 3). To assess the effects of HDACis on the transcriptional programs regulated by *EVII*, we interrogated our data with four well-validated gene signatures for statistically significant enrichment by single-sample gene set enrichment analysis (ssGSEA)³⁰. We incorporated the following databases: Molecular Signatures Database (MSigDB) of 50 gene sets, Elsevier of 1721 gene sets, Kyoto Encyclopedia of Genes and Genomes (KEGG) of 308 gene sets, and BioPlanet datasets of 1510 gene sets (Supplementary Data 3). In each database, we combined *EVII*^{High} datasets derived from the analysis of *EVII* upregulated signatures in primary myeloid leukemias cells carrying 3q26 abnormalities (GSE14468, GSE134589)^{31,32}. Next, we determined whether any of the gene sets in our selected collection were significantly enriched in *EVII*^{High} AML treated with DMSO (control) compared to those treated with HDACis. Data from the four databases revealed that treated samples were strongly correlated with signatures associated with the modulation of *MYC* oncogene (Fig. 5A, Supplementary Fig. 7B and Supplementary Data 3).



We then set up a longitudinal study and profiled bone marrow cells of PR#002 by single-cell RNA sequencing (scRNASeq) before and after four cycles of azacitidine and entinostat (Supplementary Data 3). A cluster dimensional analysis revealed 18 groups of transcriptionally distinct cell populations, among which 15 were represented in both samples (Fig. 5B and Supplementary Data 3). After treatment, we observed a reduction of the more undifferentiated myeloid

compartment and a stimulatory effect, as seen before with HDACis³³, on the immune system cells (Supplementary Fig. 7C).

Next, we computed a score based on the combined expression of the patients' leukemic markers (*CD34*, *KIT*, *CD33*, *ANPEP*, *CD38*, *CD7*, *NCAM1*, *CD4*, *CD19*, *DNTT*, *ITGB3*, *HLA-DRA*, *HLA-DRB1*, and *HLA-DRB5*) using UCell³⁴ and identified the leukemic population (LP) in the PR#002 clone as the group of cells with score >0.2. This

Fig. 2 | Validation of HDACis as *EVII* modulators. **A** *EVII* and Δ *EVII* expression in *EVII*^{high} AML cell lines ($n = 3$ biological replicates). **B** Nuclear localization expression of *EVII* (in red) detected by immunofluorescence (IF) in *EVII*^{high} AML cell lines ($n = 3$ biological replicates). Cell nuclei were stained with DAPI (blue), scale bar: 10 μ m. **C** *EVII* and Δ *EVII* expression in TF1 cells 6 days after shRNA transduction. **D** Percentage of *EVII* mRNA relative to the control gene *RPL13A* ($\Delta\Delta$ CT) in TF1 cells 6 days after shRNA transduction. **E** Effect of *EVII* loss in TF1 cells at three or six days after shRNA selection on cell proliferation. **F** Effect of shRNA-directed *EVII* loss in the ability of TF1 to form colonies in methylcellulose compared to NT ($n = 2$ biological replicates). Scale bar: 1000 μ m. The histogram on the right shows the mean number of colonies per field 20 days after plating cells. NT = non-targeting, sh#16 and sh#87 = shRNA directed against *EVII* (**C–F**). **G** Effect of AR-42, belinostat, and entinostat on cell viability in *EVII*^{high} cell lines following 72 hours (hr) of treatment.

H Annexin V/propidium iodide (PI) staining after 72 hr of HDACis treatment. Events $\geq 20,000$. **I** Apoptotic fold increase, expressed as a percentage of annexin V-positive cells relative to vehicle control. **J** Effect of HDACis on the ability of 3q26 AML cell lines to form colonies in methylcellulose. Representative images of UCSD/AML1 treated with vehicle (DMSO), 0.5 μ M AR-42, 0.5 μ M belinostat, and 0.5 μ M entinostat ($n = 3$ biological replicates). Scale bar: 1000 μ m. **K** The histogram shows the mean number of colonies per field 20 days after plating cells ($n = 3$ biological replicates). Statistical significance among groups was determined by one-way (**D**, **K**) or two-way (**E**) ANOVA using Tukey's correction for multiple comparison testing. Data are presented as mean $\pm$ standard deviation (SD) in **D** ($n = 3$), **E** ($n = 4$), **F** ($n = 10$ fields per condition), **G** ($n = 2$), and **K** ($n = 10$ fields per condition). Source data are provided as a Source Data file. See also Supplementary Fig. 3.

population accounts for 29.5% of the sample and is predominantly composed of hematopoietic stem cells (HSCs) (61.4%) and lymphomyeloid primed progenitor (LMPP) (31.6%) cell types. After therapy, LP decreased to 3.1% while maintaining a similar proportion of the cluster distribution (70.7% HSCs and 20.2% LMPP) if compared with the sample before treatment (Fig. 5C, Supplementary Fig. 7D and Supplementary Data 3).

In HSCs, LMPP, or LP cells, highly expressed genes are correlated with Myc-associated gene sets, suggesting an inhibitory effect on Myc signaling after azacitidine and entinostat treatment in human 3q26 AML (Fig. 5D, Supplementary Fig. 7E and Supplementary Data 3). Consistently, we observed a reduction in MYC expression in the leukemic cells in the bone marrow of PR#002 after two cycles of azacitidine and entinostat (Fig. 5E). Perhaps it was not surprising that genetic or HDACi-mediated suppression of *EVII* led to a decrement of MYC in ex vivo *EVII*^{high} AML patient blasts and cell lines (Fig. 5F, Supplementary Fig. 7F, G). This result is consistent with ChIP-Seq findings that reveal a binding of *EVII* at the *MYC* promoter locus marked by acetylated histone H3K27 (H3K27Ac). This pattern is significantly diminished following treatment with HDACis (Supplementary Fig. 7H).

Next, we asked whether azacitidine contributed to the clinical response seen in 3q26 AML patients and whether azacitidine played a part in the observed phenotypes. Then, we recapitulated our clinical protocol testing azacitidine and entinostat in a 3q26 PDLX model. We showed that entinostat controls proliferation, *EVII* modulation and a Myc signaling of PDLX_PR#008 LP (Fig. 5G–I and Supplementary Fig. 7I) with minimal contribution from azacitidine (Fig. 5J–L).

Finally, to exclude a direct effect of HDACis on MYC as previously reported for other cancers^{35–37} we compared the effects of AR-42, belinostat and entinostat in AML MYC^{high} versus MYC^{low} (Supplementary Fig. 8A, B) or by overexpressing *MYC* in the U937T inducible model (Supplementary Fig. 8C, D). Differently from *EVII*, in these models *MYC* did not render cells more sensitive to HDAC inhibition whereas, as expected, it exhibited this effect for JQ-1, a potent repressor of *MYC* superenhancers (Supplementary Fig. 8E, F)³⁸. While we cannot exclude an effect of azacitidine on the leukemia response in humans, these results suggest that an HDAC epigenetic-based therapy limits Myc pathways in 3q26 AML and that azacitidine-based protocols may not be as effective in 3q26 AML as they are in other AML subgroups.

PA2G4 bridges *EVII* with Myc signaling

To prioritize any significant pathway scored by ssGSEA, we dissected the *EVII* chromatin-associated complex by rapid immunoprecipitation mass spectrometry (MS) of endogenous proteins (RIME)³⁹. We performed these experiments in UCSD/AML1 and HNT34 cell lines and cells derived from the PDLX_PR#003 model. This model retained the parental t(3;3)(q21.3;q26.2) and *EVII* expression in the tumor mass (Supplementary Fig. 9A, B). We identified 107 *EVII*-interacting proteins in HNT34 cells, 117 in UCSD/AML1, and 155 in the PDLX model sample


(Fig. 6A). Sixty-nine were common in all samples (Supplementary Fig. 9C and Supplementary Data 4). Among *EVII* protein partners, we found that translation-related proteins were represented prominently, as well as translational initiating factors (1), ribosomal proteins (47) and RNA binding factors (2), transcription factors (2), histones (2), and DNA and RNA processing proteins (4). A small group of proteins with heterogeneous functions (CENPV, RPN1, FBL, SND1, PARP1, PA2G4, PABPC1, RACK1, MTDH, and ESYT1) was also recovered. In addition, *EVII* partners identified by stable isotope-labeling amino acids in cell culture-based quantitative proteomics, such as PARP1, XRCC5, RPS19, and H2AZ⁴⁰ (Supplementary Data 4), were also identified by our approach.

We intersected the 69 hits with the enriched genes scored by ssGSEA. Eleven of the 69 RIME targets were represented in the *MYC Target V1 pathway*. In all other instances, the intersection resulted in two or fewer hits, suggesting that *EVII* and Myc signaling share co-regulators in their transcriptional machinery (Supplementary Fig. 9D and Supplementary Data 4). Ten out eleven these proteins were confirmed by repeating the analysis of MS RIME data with a label-free quantification (LFQ) approach (Supplementary Fig. 9E and Supplementary Data 4). A difference in *EVII*-dependent transcriptional regulation was demonstrated with HDACis in only 3 of 11 common hits: Fibrillarin (*FBL*: log₂ fold change = −0.74, Adj.P = 0.017), nucleolar RNA helicase 2 (*DDX21*: log₂ fold change = −0.69, Adj.P = 0.006), and, proliferation-associated 2G4 (*PA2G4*: log₂ fold change = −1.45, Adj.P = 1.34×10^{-06}) (Fig. 6B, C and Supplementary Data 3) that was retained for validation since, in our model, *PA2G4* interacts with *EVII* (Fig. 6A and Supplementary Fig. 9F, G) and is transcriptionally repressed by HDACis treatment (Supplementary Fig. 9H).

PA2G4 is involved in protein translation, cell cycle progression^{41–43}, and a cancer-druggable feed-forward transcriptional regulator of *MYCN* in neuroblastoma⁴⁴. Similarly, *PA2G4* is positively correlated with *MYC* expression in AML primary datasets (GSE14468, $n = 524$ and GSE134589, $n = 672$; Supplementary Fig. 9I)^{45,46} and interestingly, both *EVII* and *MYC* occupy the promoter region upstream *PA2G4* transcription site (Supplementary Fig. 9J), suggesting that these genes are required for *PA2G4* control in 3q26 leukemia (Fig. 6B).

We next addressed whether the effect of HDACis on *EVII* was at least partly related to *PA2G4* and showed that *PA2G4* knockout abrogates *EVII* and consequently MYC protein (Fig. 6D); it then prevents the growth and formation of colonies in 3q26 AML (Supplementary Fig. 10A, B). Conversely, the overexpression of *PA2G4* increased *EVII* and MYC protein levels (Fig. 6E and Supplementary Fig. 10C) and partially rescued AML cells from the apoptotic effect of HDAC inhibition (Fig. 6F), suggesting that *PA2G4* is a putative mediator of HDAC inhibition.

Because genetic loss of *PA2G4* occurs in the absence of transcriptional regulation of *EVII* or *MYC* (Fig. 6G), we speculated that *PA2G4* protects *EVII* from proteasome degradation, as seen for *MYCN* in neuroblastoma⁴⁴. Consistently, MG132 treatment partially rescues



the EVI1 level in 3q26 AML cell lines (Fig. 6H and Supplementary Fig. 10D), suggesting that PA2G4 acts as a scaffolding protein for EVI1 transcriptional complex.

Taken together, our data suggest that PA2G4 bridges EVI1 to MYC and supports the disruption of this protein to diminish their respective oncogenic signals in this leukemia subtype.

Selective PA2G4 inhibitor WS6 depletes EVI1 and MYC signaling and blocks 3q26 AML in vivo

The selective PA2G4 inhibitor, WS6, was recently identified on high-throughput screening for inducers of β pancreatic islet cells⁴⁷. WS6 is a diarylurea compound that interferes with PA2G4-MYC binding⁴⁴. Given the homology of MYC to MYCN⁴⁸, we tested this molecule with

Fig. 3 | EVI1 sensitizes AML to HDACis. **A** EVI1, ΔEVI1, and cleaved caspase 3 expression in 3q26 EVI1^{High} cell lines after 24 hr of treatment with DMSO or HDACis ($n = 2$ biological replicates). **B** Representative IF images of EVI1 (red) in 3q26 EVI1^{High} cell lines (left, $n = 3$ biological replicates). Cell nuclei were stained with DAPI (blue), scale bar: 100 μm. Right: fluorescence intensity of nuclear EVI1 content in 3q26 EVI1^{High} AML cell lines after 24 hr of treatment. **C** IF images of U937T_E10 cells cultured in the presence (EVI1^{Low}, top panel) or absence (EVI1^{High}, bottom panel) of tetracycline, incubated with an anti-EVI1 (red) antibody ($n = 2$ biological replicates). Nuclei in blue (DAPI). Scale bar: 100 μm. **D** Effect of HDACis and ara-C on cell viability after 72 hr of treatment in U937T_E10 cell cultured in the presence (EVI1^{Low}, black line) or absence (EVI1^{High}, red line) of tetracycline. **E** Representative IF showing HL-60 cells transduced with an empty (top panels) or an ORF-EVI1 cDNA (bottom panels) vector and stained with an anti-EVI1 antibody (in red, $n = 2$ biological replicates). Nuclei in blue (DAPI). Scale bar: 100 μm. **F** Effect of HDACis and ara-C on cell viability after 72 h of treatment in HL-60 ± ORF-EVI1 cDNA. **G** Abnormal 3q26 pattern on fluorescence in situ hybridization (FISH) in MOLM1 sorted by cell size. The break-apart hybridization pattern IF1G10 (one fusion and two separated

signals, one green and one orange) indicates the break and split of the *EVI1* locus. The abnormal pattern was observed in cells with large nuclei. At least 100 nuclei/cells were analyzed ($n = 2$ biological replicates). Scale bar: 20 μm. **H** Expression of EVI1 in MOLM1 sorted based on cell size. Large cells express EVI1 compared to small cells. **I** Effects of HDACis and chemotherapy treatment on viability in MOLM1 EVI1^{High} and MOLM1 EVI1^{Low} after 72 h of drug exposure. **J** Effect of AR-42, belinostat, entinostat, ara-C, vincristine, methotrexate, and daunorubicin on EVI1^{High} (MOLM1, UCSD/AML1, HNT34, TF1, and MUTZ-3) and EVI1^{Low} (NOMO1, MOLM13, OCI/AML1, OCI/AML2, GDM1, SKM1, and IMS-M2) AML cell lines calculated using the area under the curve (AUC) model of the log-transformed dose-response data. A lower AUC corresponds to greater sensitivity. Statistical significance was determined by two-tailed non-parametric t-test (Mann-Whitney) (**J**), one-way ANOVA with Tukey's correction for multiple comparison testing (**B**). Data are presented as mean ± SD in **B** (UCSD/AML1 $n = 828$, MOLM1 $n = 1028$, HNT34 $n = 571$), **D** ($n = 2$), **F** ($n = 2$), **I** ($n = 2$) and **J** (EVI1^{High} $n = 5$, EVI1^{Low} $n = 7$). Source data are provided as a Source Data file. See also Supplementary Fig. 4.

the functional assays described above. WS6 inhibited cell proliferation greatly in AML EVI1^{High} vs. AML EVI1^{Low} (Figures 7A–C and Supplementary Fig. 11A) and potentiate the effect of HDACis (Supplementary Fig. 11B). To exclude the WS6 off-target effect, we demonstrated that WS6 lacks activity against HDAC in biological assays, as shown by the comparative quantification of H3K27 acetylation and β-tubulin in EVI1^{High}-treated AML cell lines (Supplementary Fig. 11C). WS6 markedly decreased MYC and EVI1 in EVI1^{High} primary blasts and EVI1^{High} AML cell lines (Fig. 7D and Supplementary Fig. 11D) and consequently their occupancy at the *PA2G4* promoter (Supplementary Fig. 9J). Similarly to HDACis, WS6 diminished EVI1 expression in circulating AML cells in 3q26 PDLX models in vivo (Fig. 7E). WS6 is a tool compound that has not yet been optimized for continuous systemic delivery; thus, we tested the tumor-suppressing capacity of this molecule by treating two 3q26 AML PDLXs (PDLX_PR#003 and PDLX_PR#008) models at 25 mg/kg for 5 days/week for 15 days. We demonstrated that IP administration of WS6 inhibited LP progression, compared to vehicle-treated control, traced by hCD45+ (Fig. 7F and Supplementary Fig. 11E) or scRNASeq quantification (Fig. 7G and Supplementary Fig. 11F). No major toxicities were seen in treated animals. In addition, EVI1 and MYC protein levels were diminished in WS6-treated tumors compared to vehicle-treated control animals (Fig. 7H, Supplementary Fig. 11G), linking growth inhibition (Ki67) to the suppression of EVI1-MYC.

Taken together, these results demonstrate that *PA2G4* is a drug-gable mediator of EVI1 complex and suggest that *PA2G4* inhibitors should be selectively optimized for clinical applications.

Discussion

Despite recent advancements in the treatment of low- and intermediate-risk AML by targeting mutationally activated kinases^{49–51} and newer initial treatment options for a subset of patients^{52,53}, high-risk AML with recurrent genetic abnormalities, such as *inv*(3)(q21.3;q26.2) and *t*(3;3)(q21.3;q26.2) remains a significant clinical challenge. In these patient subgroups, induction^{54,55} and maintenance cytotoxic chemotherapy have consistently failed to show a benefit⁵⁶. Patients with 3q26 AML, for example, eventually experience relapse, even after allogeneic hematopoietic cell transplantation with curative intent^{57,58}.

In this case, the development of a small molecule that can block the activity of EVI1 would be an attractive approach^{59–61}. Given this temporary absence, an alternative is to focus on unbiased strategies, searching for modulators in one or more leukemogenic steps in the metabolic, transcriptional, or epigenetic pathways that are aberrantly activated by EVI1 in 3q26 AML^{15,17}. Closer to clinical translation, the PARP inhibitor emerged as a transcriptional repressor of EVI1 by decreasing the interaction frequency between the *GATA2* distal hematopoietic enhancer (G2DHE) and the *EVI1* promoter⁶². However,

the risk of secondary myelodysplastic syndrome and AML in cancer patients treated with PARP inhibitors such as olaparib and veliparib⁶³ raises concerns about their use in myeloid leukemia and hematological malignancies more broadly.


Our strategy was meant to identify clinically ready solutions to modulate EVI1 in 3q26 AML. Among potential targets, we decided to validate structurally different pan-HDACis and more selective molecules in various stages of clinical development and subsequently identified a potential mediator of this response.

The functional interaction of EVI1 with the HDAC complexes was initially postulated in heterologous cells transfected with different *EVI1* cDNAs isoforms^{64–66} or by quantitative proteomics combined with yeast two-hybrid screens and subsequently validated by coimmunoprecipitation experiments with endogenous EVI1 in cancer cell lines⁴⁰. While collectively, these studies suggest that EVI1 mainly associates and cooperates with HDAC1^{40,65,66}, HDAC2⁴⁰ (class I), or HDAC4 (class II)⁶⁷, the number of studies validating EVI1-HDAC co-transcriptional complex in human 3q26 AML and cancer models is surprisingly low.

Nevertheless, our results for EVI1 expression upon HDACis treatment place this compound class in a fascinating scenario. While HDACis have been shown to induce histone hyperacetylation, apoptosis, and anti-proliferative activities against a wide range of rearranged leukemia cell lines or mouse models preclinically, no pharmacodynamic demonstrations exist of their target engagement in AML clinical trials. Further research will be crucial to uncover their potential as therapeutic agents in 3q26 AML, particularly with the next generation of selective HDACis.

MYC is broadly altered in AMLs⁶⁸ and it is an independent prognostic factor in high-risk AMLs, especially those associated with myelodysplasia-related changes (AML-MRC)^{69–71}. Ottema and colleagues recently found that the translocation of the *MYC* super-enhancer (SE) leads to *EVI1* overexpression in *t*(3;8)(q26;q24) AML⁷². This data suggests that therapeutic approaches that interfere with TFs and co-activators docking to this prototypical location (SE-EVI1 promoter) negatively affect EVI1 expression in *t*(3;8)(q26;q24) or other 3q26 rearranged cases. However, the identification of EVI1 interactome in AML is still lacking. Previous studies identified potential EVI1 interactors in different tumor types^{40,73–76} but, given the heterogeneity of these models, the number of genes overlapping across these approaches is low.

While we confirmed the co-immunoprecipitation of previously reported putative EVI1 co-regulators, such as PARP1, XRCC5, RPS19, and H2AZ⁴⁰, we did not observe enrichment for HDACs or MYC by RIME. The interaction with the HDAC machinery, and hence the response to therapy, might be indirect and mediated by different co-regulatory proteins. We showed that *PA2G4* contributes to linking HDAC response to EVI1 loss and, in turn, to MYC suppression.



PA2G4 accounts for 10 exons and encodes two splice *PA2G4* (also known as ErbB3-binding protein 1, EBP1) variants, p48 and p42. The difference, 54 amino acids in the N-terminus, between the long and short isoforms directs unique function, oncogenic or tumor suppressive⁷⁷, and association with different binding partners and their regulation⁷⁸. p48 *PA2G4* is the dominant form that is highly expressed in mammalian cells during embryogenesis or re-expressed in several

cancer types, including glioblastoma multiforme and lung cancer^{79,80}. p42, the short form, is scarcely detectable in cancers, while its tumor-suppressive role has been established in several tumor models^{80–82}.

Similar to a *MYCN*-dependent neuroblastoma model⁴⁴, the genetic and chemical disruption of the *PA2G4*-MYC interface with the small molecule inhibitor WS6⁴⁷ altered AML cell proliferation, supporting an oncogenic role of *PA2G4* in 3q26 AML. In AML, the mechanistic role of

Fig. 4 | Effect of HDACis in human 3q26 *EVII*^{High} AML. **A** H&E histological sections of PR#003 bone marrow cells grown in collagen type I scaffolds with vehicle (DMSO) or HDACis (AR-42, belinostat, and entinostat) for 72 hr. Scale bar: 40 μ m. **B** Percentage of cell viability of primary 3q26 AML grown in collagen type I scaffolds and treated with HDACis. Scale bar: 100 μ m. Drug concentration (IC_{50}) used in (**A**) and (**B**) were established following a dose-response titration assay presented in Supplementary Fig. 6A. **C** AUC effect of HDACis and chemotherapy agents in *EVII*^{High} (samples PR#002-008, and PR#023-024) and *EVII*^{Low} (samples PR#010-022, and PR#025-039) AML blasts. **D** *EVII*, Δ *EVII*, and cleaved caspase 3 protein expression of primary 3q26 AML samples after 24 h of treatment with the indicated concentrations of HDACis. **E** Representative images of IF staining of primary 3q26 *EVII*^{High} AML cell showing *EVII* nuclear content (in red) following 24 hr of treatment with DMSO or HDACis at the indicated concentrations ($n = 3$ biological replicates). Nuclei in blue (DAPI), scale bar: 100 μ m. **F** Quantitative IF analysis of nuclear *EVII* content in 3q26 *EVII*^{High} primary AML cells after 24 h of treatment with indicated

compounds. **G** Effect of entinostat (left) or ara-C (right) on *EVII* nuclear localization (in red) following 6 hr of treatment in PR#003 or PR#004, respectively. The nuclei were stained with DAPI (blue). Scale bar: 100 μ m. IF quantification of *EVII* nuclear content is presented at the bottom. **H** *EVII* expression (brownish) in bone marrow leukemia cells at diagnosis and following two cycles of azacitidine and entinostat (PR#002, left) or three cycles of ara-C and daunorubicin (3 + 7) (PR#004, right). Top, formalin-fixed, paraffin-embedded (FFPE) tissue sections were stained with anti-*EVII* antibody revealed by immunoperoxidase. Scale bar: 100 μ m. Statistical significance was determined by a two-tailed non-parametric t-test (Mann-Whitney) (**C**, **G**, **H**) or one-way ANOVA with Tukey's correction for multiple comparison testing (**B**, **F**). Data are presented as mean $\pm$ SD in **B** (PR#003 $n = 3$, PR#004 $n = 2$), **C** (*EVII*^{High} $n = 9$, *EVII*^{Low} $n = 28$), **F** (PR#002 $n = 318$, PR#003 $n = 573$), **G** (PR#003 $n = 235$, PR#004 $n = 214$), and **H** ($n = 10$ fields per condition). Source data are provided as a Source Data file. See also Supplementary Fig. 5-6 and Supplementary Data 2.

PA2G4 has not yet been investigated. Previous studies demonstrated that PA2G4 is highly expressed in AML clinical samples compared to mononuclear cells from healthy donors⁸³. However, since only a few cases have been cytogenetically characterized⁸³, it is impossible to speculate whether patients carrying 3q26 aberrancies express a higher level of PA2G4 than do other subgroups. Interestingly, PA2G4 is part of a transcriptional core signature of four genes (*DNMT1*, *MYB*, *PA2G4*, and *YBX1*) repressed with de-differentiation in all-trans retinoic acid-induced NB4 and HL60 AML cell lines, suggesting that PA2G4 plays a role in AML maintenance⁸⁴. Furthermore, in the murine myeloid precursor 32D cell line, PA2G4 participates in the regulation of HDAC8 ubiquitination that is disrupted by the forced expression of the *Cbfb-MYH11* fusion, indicating a contribution of PA2G4 in MDM2-mediated HDAC8 ubiquitination in inv(16) leukemia⁵⁹.

In conclusion, we propose a clinical treatment strategy that capitalizes on the *EVII*-suppressing capacity of some HDACis in patients carrying 3q26 abnormalities that lack biomarker-directed treatment approaches. Furthermore, based on the mechanism driving efficacy upon HDAC inhibition, our work positions PA2G4 as a drugable target for a neglected population with *EVII*-expressing AML and potentially for other Myc-dependent cancers.

Methods

Cell lines


The human cell lines MOLM1 (#ACC 720), UCSD/AML1 (#ACC 691), HNT34 (#ACC 600), TF1 (#ACC 334), MUTZ-3 (#ACC 295), 293 T (#ACC 635), OCI/AML3 (#ACC 582), MOLM13 (#ACC 554), NOMO1 (#ACC 542), OCI/AML2 (#ACC 99), GDM1 (#ACC 87), HL-60 (#ACC 3), SKM1 (#ACC 547) and 5637 (#ACC 35) were purchased from the Leibniz-Institut DSMZ-German collection of microorganisms and cell cultures (Germany). IMS-M2 were previously reported in⁸⁵. U937T and U937T_E10 were a kind gift from the Rotraud Wieser laboratory (University of Vienna, Clinic of Medicine I, Waehringer Guertel 18-20, 1090 Vienna, Austria). Cells were cultured in RPMI 1640 (Thermo Fisher Scientific, Waltham, MA, USA, #31870074) with 10% or 20% fetal bovine serum (FBS) (Thermo Fisher Scientific, #10270106) and 1% penicillin-streptomycin (EuroClone, Pero-Milan, Italy, #ECB3001D). UCSD/AML1 medium was supplemented with 10 ng/mL rhGM-CSF (ProteinTech Group, Rosemont, IL, USA, #HZ-1002). MUTZ-3 cells were maintained in DMEM (Thermo Fisher Scientific, #11965118) with 20% FBS, 20% 5637 conditioned medium, and 2 mmol/L L-glutamine (Thermo Fisher Scientific, #25030-024). The tetracycline-repressible U937T and U937T_E10 were cultured in RPMI 1640 containing 10% tetracycline-free FBS (Takara Bio Europe SAS, Saint-Germain-en-Laye, France, #631367). 293 T cells were cultured in DMEM, 10% FBS, and 1% penicillin-streptomycin. Cell lines were grown in a humidified incubator at 37 °C and 5% CO₂, routinely identified by short tandem repeat profiling, and monitored for mycoplasma contamination.

Clinical AML samples and patients

Leukemia cells derived from the peripheral blood and bone marrow of patients with 3q26 AML were obtained under approved protocols at the Department of Medicine and Surgery at Parma University Hospital (n. 18249/18/05/2017, and n. 29785/13/07/2021), according to the Declaration of Helsinki guidelines for the protection of human rights. Mononuclear cells were isolated by density gradient centrifugation using an LSM-lymphocyte separation medium (Cappel™ MP Biomedicals, Solon, OH, USA, #50494). We collected a total of 39 samples (Male = 18; Female = 21; mean age = 64.4 -25-87-). Bone marrow biopsies were collected according to the protocol n. 265/2019, granted by the same Institution. All biological samples were collected after the release of a written informed consent. Three patients (PR#001, PR#002, and PR#003) were enrolled in a compassionate use program (the treatment schedule was described in the NCT00101179 clinical trial), they have provided written consent and they did not receive compensation. Individuals agreed to participate in our study and having their data reported for scientific purposes. No sex and/or gender was considered in the design of this study.

Karyotype analysis and fluorescence in situ hybridization

Primary leukemic blasts were isolated as described in the previous section and cultured for 48 hr in RPMI 1640 in a humidified incubator at 37 °C and 5% CO₂. Cell media was supplemented with 0.1 μ g/mL of colcemid (Thermo Fisher Scientific, #15212012) for 2 hr, followed by incubation in a hypotonic solution (0.075 M KCl). Cells were fixed in a 3:1 methanol (Sigma-Aldrich, St. Louis, MO, USA, #322415) and acetic acid glacial fixative solution (Sigma-Aldrich, #A6283) and spread on top of Superfrost Plus microscope slides (Thermo Fisher Scientific, #10149870). For the karyotype analysis, chromosome banding was performed by quinacrine (Q-banding) or Giemsa (G-banding) staining. A minimum of 20 metaphases per sample were acquired using a Nikon Eclipse 80i microscope (Nikon Instruments, Inc., Melville, NY, USA) and analyzed using NIS element software (Nikon Instruments, Inc.). For the fluorescence in situ hybridization (FISH) analysis, 10 μ L of *MECOM/RUNX1* t(3;21) fusion (Kreatech Biotechnology B.V., Amsterdam, The Netherlands, # KBI-10310) or *MECOM* t(3;3); inv(3)(3q26) break-apart translocation probes (Kreatech Biotechnology B.V., # KBI-10204) were incubated at 37 °C for 12-16 hr after a phase of DNA dehydration with ethanol-scale incubation (75–85–100%) and DNA denaturation [75 $\pm$ 1 °C 5 minutes (min)]. Slides were washed once with 0.4x saline sodium-citrate/0.3% NP40 buffer at 73 $\pm$ 1 °C, followed by 4 x SSC/0.1% NP-40 at ambient temperature. DNA was counterstained with 4',6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, #10236276001) before microscope analysis (Eclipse 80i microscope, Nikon Instruments, Inc.). Two-hundred interphase nuclei and at least 6 metaphases were analyzed for each patient, and DNA rearrangements were defined starting from a 5% cutoff for each probe.



Small molecule screening assay

We screened 5349 compounds in duplicates, including i) the Spectrum Collection library (MicroSource Discovery System, Inc., Gaylordville, CT, USA) containing 1200 FDA/EMA-approved drugs, 500 natural products, and 300 molecules in preclinical stages for a total of 2000 compounds; ii) the anti-cancer compound library (Selleck Chemicals, Houston, TX, USA), containing 349 bioactive compounds with known

anti-cancer activity; and iii) the NDL-3000 library (TimTec, Tampa, FL, USA) containing 3000 natural derivative compounds. MOLM1 and UCSD/AML1 cells (1.5×10^3 per well) were plated in 384-well tissue culture plates in 45 μ L of medium using the BioTeck EL460 automated cell dispenser (BioTeck) and incubated for 72 h. Small molecules were screened at the final concentration of 1 μ M dissolved in (dimethyl sulfoxide) DMSO added by a Tecan Evo200 (Tecan, Switzerland).

Fig. 5 | HDAC-mediated suppression of *EVII* modulates Myc signaling.

A Heatmap showing ssGSEA enrichment of MSigDB of gene signature in MOLM1 and UICSD/AML1 HDACi-treated cells. Hot or cold colors indicate correlation or anticorrelation of the top enriched gene sets from each functional group ($P \leq 0.05$ in bold, calculated according to³⁰) among cell lines and treatments (bottom). **B** Uniform manifold approximation and projection (UMAP) plot of clustering results of PR#002 bone marrow cells before and after therapy. Colors indicate the cell populations on the basis of the reference mapping approach. **C** UMAP plot of clustering results of PR#002 bone marrow cells before (left) and after (right) therapy, colored according to the UCell score of leukemic markers. **D** GSEA running score plot of the top enriched *MYC targets V1 pathway* in HSC, LMPP, and LP ($Adj.P = 0.0011$) cell populations of PR#002. Each graph indicates the running enrichment score (ES) of the pathway (top), the location of single genes of the gene set in the ranking (central), and the distribution of the ranking metric (bottom). **E** MYC expression (brownish) in bone marrow leukemia cells of PR#002 at diagnosis and following two cycles of azacitidine and entinostat (left). Scale bar: 100 μ m. Right, the scatter dot blot indicates the mean $\pm$ SD of the percentage of the MYC-positive cells in FFPE tissue sections ($n = 10$ fields per condition). **F** *EVII*, Δ *EVII*, and MYC expression in *EVII*^{High} AML cell lines, 6 days after shRNA transduction. NT = non-targeting, sh#87 = shRNA directed against *EVII* ($n = 3$ biological replicates). **G** In vivo antileukemic effect of entinostat and azacitidine. Mice (PDLX_PR#008) were treated with vehicle (DMSO), azacitidine (1 mg/kg) for 5 days, entinostat (10 mg/kg) (5 days/week) or the combination of both for 3 weeks. Histograms show the percentage hCD45⁺ in bone marrow (top) and the percentage of *EVII* mRNA relative to the control gene *RPL13A* ($\Delta\Delta$ CT) in CD45⁺ cells (bottom) at the end of treatment. **H** UMAP plot of clustering results of PDLX_PR#008 bone marrow LP before (i) and

after entinostat (ii), azacitidine (iii) or the combination of both (iv), colored according to the UCell score of leukemic markers. **I** GSEA running score plot of the top enriched *MYC targets V1 pathway* in PDLX_PR#008 LP after the treatment with azacitidine/entinostat ($Adj.P = 3.40 \times 10^{-8}$) or entinostat as a single agent ($Adj.P = 2.17 \times 10^{-12}$). Each graph indicates the running enrichment score (ES) of the pathway (top), the location of single genes of the gene set in the ranking (central), and the distribution of the ranking metric (bottom). **J** Dot plot of GSEA results illustrating Molecular Signatures Database (MSigDB) biological processes associated with the indicated treatments compared to the vehicle in PDLX_PR#008 LP. Set size refers to the number of genes associated with each (MSigDB) biological process. Dot color indicates the range of $Adj.P$ for each pathway. **K** *EVII*, MYC, and Ki67 expression (brownish) in bone marrow leukemia cells (PDLX_PR#008) following three weeks treatment of azacitidine and entinostat as described in panel **G**. FFPE tissue were stained with anti-*EVII*, anti-MYC and anti-Ki67 antibodies revealed by immunoperoxidase. Scale bar: 100 μ m. **L** Histograms display the mean $\pm$ SD of the percentage of the *EVII*, MYC or Ki67-positive cells in FFPE tissue sections. Statistical significance was determined by a two-tailed non-parametric t-test (Mann-Whitney) (**E**), and one-way ANOVA with Tukey's correction for multiple comparison testing (**G**, **L**). GSEA enrichment score significance was based on a weighted Kolmogorov Smirnov (WKS) test corrected for multiple hypotheses testing; Benjamini & Hochberg (BH or FDR) (**D**, **I**, **J**). Data are presented as mean $\pm$ SD in **E** ($n = 10$ fields per condition), **G** (vehicle $n = 7$, treated $n = 5$ per group; $n = 9$ for the bottom panel), **K** (vehicle $n = 7$, treated $n = 5$ per group), **L** ($n = 10$ fields per condition). Source data are provided as a Source Data file. See also Supplementary Fig. 7-8 and Supplementary Data 3.

DMSO and etoposide (5 μ M) treated cells were used as negative (vehicle) and positive controls, respectively.

The effect on cellular viability was quantified using an ATP-based Cell Titer-Glo assay (Promega Corporation, Madison, WI, USA, #G7573), and presented as a percentage of viable cells over control (POC). We also defined the normalized percentage of cell death (Δ POC) on the basis of the average of duplicates (POC_molecules, Supplementary Data 1) using the following formula: [negative controls luminescence (DMSO) – sample luminescence]/[negative controls luminescence (DMSO)] $\times$ 100. POC_molecule values for each compound have been compared to the DMSO control values ($n = 24$) using an ANOVA test applied to a linear regression model. The resulting p-values were adjusted for the multiple comparisons using the Benjamini & Hochberg (BH or FDR) method included in the p.adjust function implemented in the stats R package. We prioritized hits on the basis of the 95th percentile limit of the highest statistically significant Δ POC [Benjamini-Hochberg $P \leq 0.05$]. We then calculated all pairwise distances between the given fingerprints of the top candidates and fit a beta distribution to the resulting Tanimoto scores, conditioned on the number of set bits in each fingerprint (ChemmineR package). The resulting matrix was clustered using the hclust function in the stats package with Euclidean distance and the average agglomeration method.

Forty compounds listed in Supplementary Data 2 were counter-screened in additional cell lines (HNT34, NOMO1, and THP1) in a six-log [concentrations] dilution ranging from 10 μ M to 30 nM. The tertiary screen in TF1 assayed 4942 small molecules from the annotated libraries derived from the Selleck and Sigma-Aldrich collection available at the screening unit of the Leibniz-Forschungsinstitut of Molecular Pharmacology (FMP) and listed in Supplementary Data 1. BRAID analysis of combined drug action was calculated according to⁸⁶.

High-throughput in silico screening

Marker genes for the *EVII* “On” vs. “Off” signature were chosen using publicly available Affymetrix microarray expression profiling data on TF1 cells transduced with shRNAs targeting *EVII* (E-GEOD 16238) or from mRNA quantification in AML cell lines harboring 3q26 aberration (E-MTAB-2225)⁴⁵. For the TF1 study, we then inferred marker genes to the ConnectivityMap^{20,87} (CMap) database (<https://clue.io/lincs>), while

for the cross-validation set in *EVII* repressed HNT34 or AML^{High} vs. AML^{Low} with the The Library of Integrated Network-Based Cellular Signatures (LINCS)⁸⁸. We used the parametric bootstrap method on sets of molecules to calculate the enrichment of compound classes⁸⁹. CMap and LINCS/L1000FWD are accessible at <https://clue.io/lincs> and <https://lincsproject.org/>, respectively.

Cell treatment and viability assay


AR-42 (#S2244), belinostat (PXD101, #S1085), entinostat (MS-275, #S1053), cytarabine (ara-C, #S1648), vincristine sulfate (#S1241), daunorubicin HCl (#S3035), methotrexate (#S1220), WS6 (#S7442), (+)-JQ-1 (#S7110) and MG132 (#S2619) were obtained from Selleck Chemicals. Cell solution (50 μ L/well of 0.02×10^6 /mL) was dispensed in 384-well plates (Corning Life Sciences Plastic, Bedford, MA, USA, #3570) using MultidropTM Combi (Thermo Fisher Scientific, #5840300). According to the manufacturer's protocol, small molecules were dissolved in DMSO or ddH₂O and added with a nanometric Tecan D300e dispenser (Tecan Trading AG, Switzerland) at the concentration indicated in the figures. Cell viability was assessed after 72 hr of drug treatment using a CellTiter-Glo ATP assay (Promega Corporation, #G7573). Values for IC₅₀ and the area under the curve (AUC) were calculated using GraphPad Prism 8 software (La Jolla, CA, USA).

Apoptosis and DNA content assays

Apoptosis was measured by annexin V (annexin V, FITC conjugate, Thermo Fisher Scientific, #A13199) and propidium iodide (Thermo Fisher Scientific, #BMS500PI) staining. Cells were analyzed by flow cytometry with a FACScan (Beckman Coulter-Cytomics FC 500, Brea, CA, USA) or Attune NxT (Thermo Fisher Scientific) flow cytometry, and data were processed by FlowJo V10 (Tree Star, LLC, Ashland, OR, USA) analytical software. Cellular DNA content was assessed by staining with propidium iodide (50 μ g/mL). At least 20,000 events were acquired, and all of the determinations were replicated at least twice.

Methylcellulose assay

Clonogenic assays were performed using the MethoCultTM colony-formation assay (STEMCELL Technologies, Vancouver, BC, Canada, #GFH84444). In brief, a 10x concentrated AML cell suspension was



prepared and mixed with thawed MethoCult™ in a 1:10 v/v ratio of cells: MethoCult™. Samples were vortexed thoroughly and left to stand for at least 5 min to allow bubbles to rise to the top before dispensing; they were then incubated at 37 °C, in 5% CO₂, with 95% humidity for 15–20 days. Colony identification and counting were performed using an EVOS FL inverted microscope (Thermo Fisher Scientific) equipped with 4x and 10x objectives.

Immunodetection and antibodies

Whole protein lysate was extracted using 1x cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA, #9803 S) supplemented with phospho-stop phosphatase inhibitor (Sigma-Aldrich, #04906837001) or protease/phosphatase inhibitor cocktail 100x (Cell Signaling Technology, Danvers MA, USA, #58725) and Complete Mini, EDTA-free protease inhibitor (Sigma-Aldrich, #11836170001). Cells were lysed on

Fig. 6 | PA2G4 mediates the effect of HDACis on EVII and MYC. A Circle plot showing chromatin-associated proteins immunoprecipitated with an anti-EVII antibody by RIME. The bar length indicates the mean of mass spectrometry spectral count (SPEC) of uniquely identified proteins of two biological replicates per condition. Bar colors indicate protein ontology of the EVII interactors. **B** Histograms show the normalized gene expression levels of *SERBP1*, *RPL14*, *RPL18*, *RPS2*, *PA2G4*, *RPS10*, *FBL*, *PABPC1*, *RACK1*, *RSL1D1*, and *DDX21* following 16 hr of 0.5 μ M AR-42, 2 μ M entinostat in UCSD/AML1, or 0.8 μ M AR-42 and 4 μ M entinostat in MOLM1 compared to vehicle. Statistical significance was determined using DESeq2. Whiskers show median values (central black lines) and 25th and 75th percentiles (bottom and top bounds), respectively. The bars represent values that exceed 1.5 times the interquartile range (IQR) from the edge of each box: (vehicle $n = 6$, treated $n = 12$). **C** Tracks showing EVII binding and H3K27ac enrichment across the *DDX21*, *FBL*, and *PA2G4* locus in HNT34 cells treated with vehicle (DMSO), AR-42 and entinostat. The bottom bar represents the genes (hg19), and the y-axis represents normalized read density scaled to 1 million. **D** PA2G4, EVII, Δ EVII, and MYC expression in TF1, HNT34, and UCSD/AML1 cells 6 days after shRNA transduction ($n = 3$ biological

replicates). **E** Effect of *PA2G4* overexpression on HNT34 cells treated with HDACis. Western blot analysis showing PA2G4, EVII, Δ EVII, and MYC in wild-type or *PA2G4*-overexpressing HNT34 cells after 24 h of treatment with HDACi at the indicated doses ($n = 2$ biological replicates). **F** Histogram indicates the percentage of viable (white), dead (black), or rescued (red) HNT34 cells ($n = 20,000$) by the overexpression of *PA2G4* on the basis of positivity for annexin V/PI staining after 72 h of HDACis treatment ($n = 2$ biological replicates). **G** Percentage of *PA2G4*, *EVII*, and *MYC* mRNA relative to the control gene *ACTB* (Δ ACT) in HNT34 and UCSD/AML1 cells 6 days after shRNA transduction. Data are presented as mean $\pm$ SD ($n = 3$). Statistical significance was determined by a two-tailed unpaired, parametric t-test. **H** Proteasome inhibition rescues WS6-induced EVII and MYC protein degradation. EVII, Δ EVII, MYC expression, and PA2G4 in HNT34 and UCSD/AML1 cell lines after treatment with DMSO and WS6 (24 hr) or MG132 (4 hr) at the indicated concentrations ($n = 2$ biological replicates). NT = non-targeting, sh#65 = shRNA directed against *PA2G4* in **C** and **F**. Source data are provided as a Source Data file. See also Supplementary Fig. 9-10 and Supplementary Data 4.

ice for 10 min with gentle stirring and centrifuged at 21,130x g for 10 min at 4 °C. Protein assay dye reagent (Biorad Laboratories, Hercules, CA, USA, #5000006) was used for protein quantification, and 40 μ g of total lysate/sample was loaded for SDS-PAGE analysis. The following specific antibodies were purchased from Cell Signaling Technology: anti-EVII (C50E12, #2593), β -actin (8H10D10, #3700), cleaved caspase 3 (Asp175, #9661), and MYC (#9402). Anti-PA2G4 antibodies were purchased from Sigma-Aldrich (#HPA016484, #SAB1402863), Abcam (Cambridge, United Kingdom, #ab180602) and Proteintech (Rosemont, IL, USA #66055-1-Ig, #15348-1-Ap). Anti-histone H3 (acetyl K27) was purchased from Abcam (#ab4729). Anti-acetylated α -Tubulin (#sc-23950) and HSP90 (#sc-69703) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). All primary antibodies were used at a dilution factor of 1:1000. IRDye 680LT goat anti-mouse IgG (#925-68020), IRDye 800CW goat anti-rabbit IgG (#925-32211), and IRDye 680RD goat anti-rabbit IgG (#925-68071) from LI-COR Biotechnology (Lincoln, NE, USA) were used as secondary species-specific antibodies at a dilution factor of 1:10000. Signals were detected using the LI-COR Odyssey imaging system (LI-COR Biotechnology).

RNA processing and quantification

RNA was extracted using the RNeasy mini kit (Qiagen, Hilden, Germany, #74106). According to the manufacturer's protocol, cDNA was synthesized using the high-capacity cDNA reverse transcription kit (Thermo Fisher Scientific, #4368814), using 1 μ g of RNA as starting material. A quantitative real-time polymerase chain reaction (qPCR) was performed using TaqMan gene expression assays for *MECOM* (Thermo Fisher Scientific, #Hs00602795_m1), *MYC* (Thermo Fisher Scientific, #Hs00153408_m), *PA2G4* (Thermo Fisher Scientific, #Hs00854538_g1), and TaqMan[™] Universal PCR master mix (Thermo Fisher Scientific, #4364338) in an Applied Biosystems[™] StepOne[™] real-time PCR system (Thermo Fisher Scientific, #4376357). Each condition was run in triplicate. The expression levels of the target genes were normalized to those of *RPL13A* or *ACTB* (Thermo Fisher Scientific, #Hs04194366_g1, #Hs99999903_m1). Data were analyzed using the $\Delta\Delta$ cycle threshold (CT) method and plotted as a percentage relative to control.

Immunofluorescence

Cells (50×10^3) were washed in PBS and spotted on Superfrost Plus microscope slides (Thermo Fisher Scientific, #10149870) using a cytospin centrifuge (CR2000 Small Prime Centrifuge, Centurion). Fixation was carried out for 10 min in PBS, 4% paraformaldehyde (Thermo Fisher Scientific, #28908) at 4 °C. For nuclear protein staining, cells were permeabilized for 10 min in PBS and 0.4% Triton X-100 (Sigma-Aldrich, #T-9284) at ambient temperature. We applied a


blocking solution for 1 h at ambient temperature composed of 5% bovine serum albumin, 0.1% Triton X-100, and 1% goat serum (Abcam, #ab138478) diluted in PBS. Cells were then incubated for 1 hr at ambient temperature with the antibody targeting EVII (Cell Signaling Technology, #2593, 1:1000 dilution) or PA2G4 (Sigma-Aldrich, #HPA016484, #SAB1402863 both diluted 1:1000) and subsequently revealed by secondary antibodies (Invitrogen, Carlsbad, CA, USA, #A11029, #A11036, both diluted 1:400) and diluted in blocking solution. Nuclei were stained with DAPI (Sigma-Aldrich, #D9542). Prolong Gold Antifade reagent (Thermo Fisher Scientific, #P36934) was used as a mounting solution. Images were captured using an EVOS[™] M5000 microscope (Thermo Fisher Scientific) or a Leica Stellaris 5 confocal microscope. ImageJ (<http://rsbweb.nih.gov/ij/>) and Leica Image Compass were used for the analysis.

Immunohistochemistry

Informed consent was obtained from patients undergoing trephine bone marrow biopsy from the iliac crest for diagnostic procedures according to the ethical guidelines and the protocol 265/2019/TESS/UNIPR, approved by the University of Parma. Following decalcification, 4- μ m-thick sections obtained from formalin-fixed, paraffin-embedded bone marrow biopsies were processed for immunohistochemical staining. Bone marrow samples were deparaffinized and rehydrated in decreasing alcohol scale; enzymatic epitope retrieval was performed by water bath at 95 °C, 40 min, in ULTRA Cell Conditioning Solution (Ventana; 950-224); endogenous peroxidase was blocked with 3% H₂O₂. After incubation with rabbit anti-EVII (Cell Signaling Technology, #2593; 1:400 dilution; overnight; 4 °C), rabbit anti-MYC (Cell Marque[™]; Rocklin, CA, USA, #395R-18; ready to use; 40 min; 37 °C), or mouse anti-Ki67 (Agilent, Santa Clara, CA, USA, #HR626; ready to use; 30 min; 37 °C) antibodies, all sections were revealed by IHC Detection Kit-Micropolymer (Abcam #ab236466) according to manufacturer's recommendations. The nuclei were counterstained by light hematoxylin. All staining steps were performed at ambient temperature. 3D type I collagen scaffolds and xenografted tumors were fixed in formalin, included in paraffin, and processed as indicated above. Images were acquired with a MoticEasyScan One (Motic, Hong Kong) microscope and quantified using QuPath software v.0.3.2 (<https://qupath.github.io/>)⁹⁰.

Chromatin immunoprecipitation and ChIP Sequencing

Chromatin was collected from HNT34 cells (20×10^6 cells each condition) using ActiveMotif ChIP-IT[®] Express (ActiveMotif, Carlsbad, CA, USA, #53008) according to the manufacturer's instructions and sheared in 12 sets of 10-second sonication using a Branson Digital Sonifier (Thermo Fisher Scientific). Chromatin was incubated overnight at 4 °C with 10 μ g of the following antibodies: EVII (Cell Signaling Technology, #2593 S), MYC (Cell Signaling Technology,



#9402S), histone 3 at lysine 27 (H3K27Ac, Abcam, #ab4729), and rabbit IgG (Merck, #12-370). DNA was purified with AMPureXP beads (Beckman Coulter, #A63881) following the manufacturer's protocol. Real-time PCR was performed with SYBR-Green Reagents (Thermo Fisher, #4309155) on a CFX96 Real-Time PCR System (Biorad) with primers targeting the E-Box DNA binding sites in the *PA2G4* gene promoter, 500 bp upstream of the transcription starting site

region (forward: CCTCCCCGACCTAGGTGTA; reverse: GCTGAGC-GAGAGCCAGTAAC) and *MYC* gene promoter (forward: AGGGT-GAGGTCAAGCATTGT; reverse: TGGCCTTGAACCCATACTTC). Fold enrichment was calculated by dividing the input-normalized CT by the negative IgG control CT.

For Chromatin Immunoprecipitation Sequencing (ChIP-Seq), purified DNA was processed using the NEBNext® Ultra™ II DNA Library

Fig. 7 | PA2G4 suppression alters 3q26 AML proliferation in vivo. **A** Effects of WS6 treatment on viability in primary 3q26 AML samples following 72 hr of drug treatment. **B** Effect of WS6 in EVI1^{high} (samples PR#002 - 006, PR#008 and PR#023 - 024) and EVI1^{low} (samples PR#025-039) primary AML samples. The AUC model of the log-transformed dose-response data is depicted. **C** Effects of WS6 treatment compared to control (DMSO) on viability in primary 3q26 AML samples following 72 hr of drug treatment. Left: H&E of PR#005 bone marrow cells in 3D cell culture after 72 hr of treatment with vehicle (DMSO) or WS6 at 1/2 IC₅₀ and IC₅₀ concentrations. Scale bar: 40 µm. Right: histograms indicate the fraction of viable cells expressed as a percentage relative to control. **D** PA2G4, EVI1, ΔEVI1, and MYC and cleaved caspase 3 protein expression in primary 3q26 AML samples following 24 h of treatment with the vehicle (DMSO) or WS6 at the indicated concentrations. **E** Effect of WS6 (50 mg/kg) on EVI1 nuclear localization (in red) following 6 hr of treatment in PDLX_PR#009 (*n* = 3 biological replicates). Nuclei in blue (DAPI). Scale bar: 100 µm. Histograms indicate the fluorescence intensity of EVI1 nuclear content before and after treatment. **F** In vivo antileukemic effect of WS6. On the top the draft of the experiments. Mice were treated with vehicle (DMSO) or 25 mg/kg WS6 for 5 days/week for 15 days. On the bottom-left dot plot showing the number of hCD45+ cells expressed as the percentage difference of BM leukemic cells at T1

(endpoint-day 15) vs. T0 (pre-treatment-day 0) normalized for T0 in control (*n* = 7) and WS6-treated PDLX_PR#003 (*n* = 6). On the bottom-right the dot plot shows the percentage of hCD45+ cells in the bone marrow between vehicle (*n* = 4) or WS6-treated PDLX_PR#008 (*n* = 5) at the endpoint. Events ≥ 20,000. **G** UMAP plot of clustering results of PDLX_PR#003 hCD45 bone marrow-positive cells before (left panel) and after (right panel) 15 days of WS6 treatment (25 mg/kg/IP/5 days a week), color-coded according to the UCell score of leukemic markers (MECOM, MYC, CD45, CD34, KIT, CD33, ANPEP, CD38, CD2, TFRC, HLA-DRA, HLA-DRB1, and HLA-DRB5). **H** EVI1, MYC, and Ki67 expression in PDLX_PR#003 after 15 days of WS6 treatment (25 mg/kg/IP/5 days a week) or vehicle (DMSO). Scale bar: 100 µm. Histograms to the right indicate the mean ± SD of the percentage of the EVI1, MYC, or Ki67-positive cells in FFPE tissue sections. Statistical significance was determined by a two-tailed non-parametric t-test (Mann-Whitney) (**B**, **E**, **F**, **H**). Data are presented as mean ± SD in **A** (*n* = 2), **B** (EVI1^{high} *n* = 8, EVI1^{low} *n* = 15), **C** (*n* = 2), in **E** (*n* = 125), **F** (vehicle PDLX_PR#003 *n* = 7, treated PDLX_PR#003 *n* = 6, vehicle PDLX_PR#008 *n* = 4, treated PDLX_PR#008 *n* = 5) and **H** (vehicle *n* = 7, treated *n* = 6; *n* = 10 fields per condition). Source data are provided as a Source Data file. See also Supplementary Fig. 11.

Prep Kit (#E7645, New England Biolabs, Ipswich, MA). The final libraries were paired-end sequenced using a 150-cycle kit on NovaSeq 600 (Illumina) with a sequencing depth of 50 million reads per samples. Sequencing data were analyzed using the nf-core ChIP pipeline (version 2.0.0)⁹¹ that utilizes MACS2 for peak calling⁹² and HOMER for annotation of peaks⁹³. Normalized BigWig files were scaled to 1 million mapped reads to be able to compare coverage across multiple samples. Tracks illustrating read coverage and representative peaks were visualized using the IGV genome browser with Human (GRCh37/hg19) genome⁹⁴. A range of ± 2 kb of the transcriptional start site (TSS) was retained to define promoter-specific peaks.

Co-Immunoprecipitation

For the endogenous co-immunoprecipitation, HNT34 cells were lysed in modified Cell Lysis Buffer II (Invitrogen #FNN0021) supplemented with Protease and Phosphatase Inhibitors (Sigma #11836153001 and #04-906-837-001) for 30 min on ice and centrifuged at 14,000 RPM for 10 min at 4 °C. The protein lysates were then incubated overnight with the following antibodies: EVI1 (Cell Signaling Technology, C50E12 #2593), PA2G4 (Proteintech 15348-1-AP), or Normal Rabbit IgG (Merck, #12-370), at a concentration of 1 µg/mg of IP reaction. Dynabeads protein G magnetic beads (Thermo Fisher, #10003D) were added for 2 hr at 4 °C the next day, and then the purified proteins were eluted in 40 µl of 1X L.B. For the overexpression in 293 T cells, cells were transfected with Lenti-hEVI1a-ORF-P2A-eGFP-IRES-Puro expressing *MECOM* or *PA2G4* ORF. 48 hr after transfection, the cells were processed similarly Co-IP experiment described above.

Scaffold-based 3D AML culture

To synthesize collagen scaffolds, an acid suspension of type I collagen was precipitated at pH 5.5 and cross-linked with 1,4-butanediol diglycidyl ether. The scaffold's porosity was generated by a freezing and heating ramp to ensure desired pore size, interconnectivity, and orientation. The materials were sterilized in 70% ethanol for 1 hr and washed in sterile Dulbecco phosphate-buffered saline (Life Technologies, Carlsbad, CA, USA). Scanning electron microscopy was used to characterize the scaffold macrostructure and microstructure. In brief, scaffolds were fixed in 2.5% glutaraldehyde 0.1 M sodium cacodylate buffer for 2 hr at 4 °C, dehydrated in a series of ethanol, dried in a desiccator overnight, and sputter-coated with platinum. Images were acquired with a Nova NanoSEM 230 (FEI, Hillsboro, OR, USA). The human AML cell lines HNT34 and MOLM1 were seeded in 2 × 9-mm scaffolds at concentrations of 0.25 × 10⁶, 0.5 × 10⁶, and 1 × 10⁶ cells. Seeding was reached by soaking 50 µL of cell suspension in dry scaffolds placed in a multi-well plate. Cells were allowed to adhere for 1 hr

at 37 °C before adding the culture medium. After 24 hr, the scaffolds were gently moved onto a new multi-well plate. The medium was replaced every 2-3 days. Cell growth was monitored after 1, 3, and 7 days by MTT assay. Scaffolds were then incubated with 1 mg/mL of MTT solution (Sigma-Aldrich) in culture medium for 2 hr at 37 °C. Cell viability was determined by reading the absorbance at 550 nm. The scaffolds were fixed in neutral buffered formalin, dehydrated in scaling ethanol solutions, and embedded in paraffin to assess cell morphology and distribution. Hematoxylin-and-eosin staining was performed in 5-µm-thick scaffold sections mounted onto Superfrost Plus microslides (Thermo Fisher Scientific, #10149870). Drug treatment was performed after 72 hr from seeding. Drug efficacy was evaluated by MTT assay, as described above. Results were presented as a percentage of cells alive relative to vehicle-treated cells. The drug concentrations that reduced cell viability to 50% of vehicle controls (IC₅₀) were calculated using GraphPad Prism 8 software (La Jolla, CA, USA).

Virus production and transduction of AML cell lines

For virus production, 3 × 10⁶ 293 T were transfected with 2 µg of pCMV-VSV-G and pCMV-deltaR8.91 vectors (kind gift from Kymberly Stegmaier laboratory, Dana Farber Cancer Institute, Boston, MA, USA). pZIP-hEVI1a-RFP-Puro vector (Transomic, Huntsville, AL, USA, #TLHSU1444) harboring the shRNA sequences listed in Table 1 was used for genetic downregulation experiments.

The Lenti-hEVI1a-ORF-P2A-eGFP-IRES-Puro (Transomic, Huntsville, AL, USA, #TLO2015.1) vectors containing the *MECOM* (NM_005241.1), *PA2G4* (Gene BankBC001951.1) and *MYC* (NM_002467.6) open reading frame (ORF) sequences were used for genetic overexpression experiments. Cells were transfected using the FUGENE6 protocol (Promega Corporation, #E2691), and viral supernatant was harvested and filtered (0.4 µm) after 72 hr. AML cells were resuspended at a concentration of 4 × 10⁶ cells per 1 mL of serum-free RPMI and spin-infected for 1 h at ambient temperature with 100 µL of lentivirus particles and 8 µg/mL polybrene (Sigma-Aldrich). Puromycin (1 µg/mL) was added for selection (Thermo Fisher Scientific, #A1113803).

Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME)

For chromatin immunoprecipitation, cells were fixed with 1% methanol-free formaldehyde (Cell Signaling Technology, #12606) for 8 min and quenched with 0.125 M glycine (Sigma-Aldrich, #G8898). Chromatin was isolated by adding lysis buffer, followed by disruption with a Dounce homogenizer (ActiveMotif, #40401). The lysates were sonicated, and the DNA sheared to an average length of 300-500 bp. Genomic DNA (input) was prepared by treating aliquots of chromatin

Table 1 | Short hairpin RNA sequences for genetic knockdown of EVI1 (shRNA#16, shRNA#87 and shRNA#88), PA2G4 (shRNA#65, shRNA#66 and shRNA#68) and Not Targeting control

Gene	ID	Sequence
EVI1	shRNA#16	3'TAAATTTCTCTTATCACTTTC 5'AAAAGTGATAAGAGAAATTTA Loop:TAGTGAAGCCACAGATG
EVI1	shRNA#87	3'TATATCATTGTCTTCATCCTCC 5'AGAGGATGAAGACAATGATATA Loop:TAGTGAAGCCACAGATGTA
EVI1	shRNA#88	3'TTCTTCAACTTCTTCATCATCC 5'AGATGATGAAGAAGTTGAAGAA Loop:TAGTGAAGCCACAGATGTA
PA2G4	shRNA#65	3'TAGTGGTCTCTGTCTGCATC 5'AATGCAGGACAGAGAACCACTA Loop:TAGTGAAGCCACAGATGTA
PA2G4	shRNA#66	3'TTCATGGTCCTTCTCTGCTGG 5'ACAGCAGAAGAAGGACCATGAA Loop:TAGTGAAGCCACAGATGTA
PA2G4	shRNA#68	3'TAATTCAGCTTTTTCATGGTCC 5'AGACCATGAAAAAGCTGAATTA Loop:TAGTGAAGCCACAGATGTA
Not Targeting		3'ATGCTTTGCATACCTTCTGCCTG 5'AAGGCAGAAGTATGCAAGCAT Loop:TAGTGAAGCCACAGATGTA

with RNase, proteinase K, and heat for de-crosslinking, followed by ethanol precipitation. Pellets were resuspended, and the resulting DNA was quantified on an ND-2000 NanoDrop spectrophotometer (Thermo Fisher Scientific). Extrapolation to the original chromatin volume allowed quantitation of the total chromatin yield. An aliquot of chromatin (150 µg) was pre-cleared with protein G agarose beads (Thermo Fisher Scientific, #15920010). Proteins of interest were immunoprecipitated using 15 µg of antibody targeting EVI1 (Cell Signaling Technologies, cat. #2593 S) and protein G magnetic beads (Thermo Fisher Scientific, #88847). Protein complexes were trypsinized to release the immunoprecipitate from the beads and digest the protein samples. Protein digests were purified using a C18 spin column (Harvard Apparatus, Holliston, MA, USA, #74-7242). The peptides were vacuum-dried using a SPD130XL SpeedVac (Thermo Fisher Scientific).

Mass spectrometry

Digested peptides were analyzed by LC-MS/MS on a Q Exactive Orbitrap mass spectrometer linked to Dionex Ultimate 3000 HPLC and a nanospray FlexTM ion source (Thermo Fisher Scientific). Samples were loaded directly onto the separation column BEH C18, 75 µm x 100 mm, 130 Å 1.7-µm particle size (Waters Corporation, Milford, MA, USA). Peptides were eluted using a 100-min gradient with a 323 nL/min flow rate. An MS survey scan was obtained for the m/z range 340–1600, and MS/MS spectra were acquired using a top 15 method, where the top 15 ions in the MS spectra were subjected to high-energy collisional dissociation. An isolation mass window of 1.6 m/z was used for the precursor ion selection, and a normalized collision energy of 27% for fragmentation. A 20-second duration was used for the dynamic exclusion.

Tandem mass spectra were extracted and analyzed by PEAKS Studio version 8 build 20. Charge state deconvolution and deisotoping were not performed. The database consisted of the Uniprot database (version 180508, 71,771 curated entries) and the cRAP database of common laboratory contaminants (www.thegpm.org/crap; 114 entries). The database was searched with a fragment ion mass tolerance of 0.02 Da and a parent ion tolerance of 10 parts per million. Post-translational variable modifications consisted of methionine oxidation, asparagine, and glutamine deamidation. Peaks studio built-in decoy sequencing and FDR determination (decoy fused method) with

a cutoff set to $-10\log P > 20$ was used to validate MS/MS-based peptide and the parsimony rules for protein identifications. A threshold of $\geq 10\log P$ of 20 was applied for peptide identifications. The weighted sum of nine parameters for peptide scoring is converted to a P value, representing the probability of false identification. Protein identifications were accepted if they could pass the $-10\log P$ of 20 and contained at least one identified unique peptide. Proteins that contained similar peptides and could not be differentiated on MS/MS analysis alone were grouped to satisfy the principles of parsimony. Proteins sharing significant peptide evidence were grouped into protein groups.

The hit list was generated by taking all proteins (sample vs. IgG control) with a spectral count of five and above from each replicate.

For a label-free quantitation (LFQ) analysis, we included technical and biological replicates ($n = 6$) in a group named “3q26 AML” and compared them to the group including all the correlative IgG controls ($n = 6$), named “Control”. The Thermo raw files were analyzed using MaxQuant (MQ) version 2.4.2.0. The LFQ intensities of proteins from MQ analysis were imported and filtered for reverse identifications (false positives), contaminants, and proteins “only identified by site”. Data were transformed to $\log_2$ scale. Then, we imputed missing values and replaced them from a normal distribution. The protein quantification and calculation of statistical significance were performed with a two-sample t-test and with a permutation-based correction controlled with an FDR threshold of 0.05. A protein was considered as EVI1's interactor if the difference between the “3q26 AML” and “Control” groups was statistically significant ($P < 0.05$), the fold change was 4, and it was identified with a minimum of two peptides.

RNA sequencing

PolyA-enriched, strand-specific RNA libraries were generated with the TruSeq mRNA stranded sample preparation kit (Illumina, San Diego, CA, USA, #20020594) starting from 1 µg of RNA from each sample. In brief, RNA was subjected to polyA selection using magnetic oligo-dT beads (Thermo Fisher Scientific, #61002). A 94 °C-incubation for 4 min partially fragmented polyA RNA. Both actinomycin-D (during the first-strand cDNA synthesis) and dUTP (during the second-strand synthesis) were used to keep the strand information. The libraries were end-repaired and adenylated before being ligated with Y-shape single-indexed adapters and amplified by 11 PCR cycles. The last purification step was performed with Ampure XP beads (Beckman Coulter, #A63882) at 0.8x to remove all adapter dimers. Each library was quantified and quality-controlled using a Qubit 4 fluorometer (Thermo Fisher Scientific) and LabChip GX (Perkin Elmer, Waltham, MA, USA). The adaptor-tagged pool of libraries was loaded onto Illumina HiSeq2500 rapid-run flow cells (SR100 chemistry) for cluster generation and deep sequencing. The raw sequence files were quality-controlled using FastQC (v 1.3) (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>, accessed in May 2020). Transcripts were aligned using the STAR package (v2.7.1a) and quantified using the “quantMode GeneCounts” function with ENSEMBL annotation and the human genome version GRCh38 as a reference. Read counts generated by STAR were analyzed using the DESeq2 R package to detect differentially expressed genes (DEGs) with an adjusted P value ($Adj.P$) less than 0.05.

Single-cell RNA sequencing

Sequencing was carried out at the University of Texas MD Anderson Cancer Center's Advanced Technology Genomics Core (PR#002 and PDLX_PR#003) or at the NGS core facility of the Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (PR#008). Cell viability was detected using the Countess II FL Automated Cell Counter (Thermo Fisher Scientific). Single cells were lysed, barcoded, and normalized for input onto the Chromium Single Cell A Chip Kit (10x Genomics, Pleasanton, CA, USA). Indexed sample libraries were pulled together and sequenced using a NovaSeq6000 SP 100-cycle flow cell (Illumina).

Sequencing reads were aligned to the human genome version GRCh38. A digital expression matrix was generated for each sample using Cell Ranger software (10x Genomics), and the data were integrated using Harmony and analyzed using Seurat (R package)^{95,96}. Cells with less than 100 genes and 500 unique molecular identifiers were excluded from the analysis. Cell types were assigned using the Seurat label-transferring method and a bone marrow-specific reference (included in the SeuratData package). Conserved markers and differentially expressed genes were identified for each cluster/cell type using the Benjamini-Hochberg method to *Adj.P* for multiple testing. Statistically significant DEGs for each cluster/cell type were used to perform a gene set enrichment analysis (GSEA) using the ClusterProfiler package and the Hallmark gene-set from MSigDB. Furthermore, the identification of the leukemic cell population was assessed by computing a transcriptional signature score using the UCell R package (score ≥ 0.2) based on the expression of leukemia-associated immunophenotype for PR#002 (CD34, KIT, CD33, ANPEP, CD38, CD7, NCAM1, CD4, CD19, DNTT, ITGB3, HLA-DRA, HLA-DRB1, and HLA-DRB5), PDLX_PR#003 (CD34, CD45 KIT, CD33, ANPEP, CD38, CD2, TFRC, HLA-DRA, HLA-DRB1, HLA-DRB5, MYC, and MECOM), PR#008 in the treated and untreated samples (CD34, KIT, CD33, ANPEP, CD38, CD2, TFRC, MECOM, HLA-DRA, HLA-DRB5, HLA-DRB1, PTPRC, MYC).

Next-generation sequencing

DNA was extracted using a Maxwell® 16 DNA purification kit (Promega, #AS1010), following the manufacturer's instructions. The concentration and purity of the DNA samples were determined with a Qubit 4 fluorometer (Thermo Fisher Scientific, #33226). Primary samples were sequenced at the NGS platform of the University-Hospital of Parma using the "Myeloid Solution" kit (Sophia Genetics SA, Saint Sulpice, Switzerland, #BS.0207.0102-48). Library preparation and sequencing were performed on a MySeq system (Illumina) following the manufacturer's instructions. Data were analyzed with Sophia DDM® software version 5.10.11.1 (Sophia Genetics SA).

Animal Models

PDLXs were established by tail vein injection of mononucleated cells (2.0×10^6) isolated from AML patients, PR#003, PR#008, PR#009, with t(3;3)(q21.3;q26.2), t(3;3)(q21.3;q26.2), and inv(3)(q21.3q26.2), respectively, into 6-week-old male non-obese diabetic, severe combined immune-deficient, interleukin (IL)-2 receptor gamma-deficient mice (NOD-*SCID* IL2Rgamma^{null}, NSG, The Jackson Laboratory, Charles River Italia). Leukemic cell engraftment was monitored every 2 weeks by flow cytometry of peripheral blood cells stained with an anti-human CD45-PE antibody (Becton Dickinson, Franklin Lakes, NJ, USA, #555483). For PDLX_PR#003, 10×10^6 cells were injected into the flank to establish a subcutaneous orthotopic model. Mice' body weight and tumor growth were evaluated every two days using caliper measurements. Tumors did not exceed 10% of the animal's body weight and had an average diameter of 15 mm. Mice were housed in specific-pathogen-free conditions (25 °C, 12-h light/12-h dark cycle, 50% humidity). Gender-based analysis was not performed because AML affects both males and females. Male mice are prioritized due to a higher incidence of AML in males compared to females. All procedures were approved under the MD Anderson (Houston, TX) Institutional Animal Care and Use Committee protocol or the N.682/2019-PR protocol at the University of Parma. Mice were sacrificed when signs of distress were observed.

For pharmacodynamic studies, three 6-week-old male NOD-*SCID* IL2Rgamma^{null} (NSG, The Jackson Laboratory, Charles River Italia) mice were treated when cell engraftment of circulating hCD45 reached at least 10% of the total mononucleated cells in peripheral blood with a single administration of 10 mg/kg entinostat (PDLX_PR#003 and PDLX_PR#009) or 50 mg/kg of WS6 (PDLX_PR#009) diluted in DMSO (Sigma-Aldrich, #276855); peripheral blood cells were collected before

and after 6 hr of treatment with HDACis for immunofluorescence analysis.

For efficacy studies we used the triple-transgenic NSG-SGM3 (NSGS)(PDLX_PR#003) mice expressing human IL3, GM-CSF (CSF2), and SCF (KITLG) or NSG (PDLX_PR#008). AML leukemia cells (1×10^6) from the PDLX_PR#003 and (10×10^6) PDLX_PR#008 model were transplanted by tail vein injection in 12- to 16-week-old male and female NSGS mice, irradiated (125 cGy) 12 hr before transplantation (PDLX_PR#003). Engraftment of human PDLX cells was monitored every 2 weeks by flow cytometry of bone marrow-aspirated samples (PDLX_PR#003) or peripheral blood (PDLX_PR#008) stained with an anti-human CD45 antibody (BD Bioscience, Franklin Lakes, NJ, USA, #AB11153499, #555482 and #555483, all diluted 1:40). Mice were selected for treatment randomization 4 to 6 weeks after transplantation when the human fraction of cells in the bone marrow was $\geq 0.5\%$ or $\geq 0.1\%$ in the peripheral blood. Entinostat (MedChemExpress, Sollen-tuna, Sweden, #HY-12163) and azacitidine (Selleck Chemicals, #S1782) were dissolved in DMSO, diluted in sterile PBS, and administered by oral gavage at 10 mg/kg per five days/week for three weeks and by intraperitoneal injection at 1 mg/kg per five days respectively. WS6 was dissolved in Tween 80 (50:50), diluted in sterile PBS, and administered by intraperitoneal injection (IP) at 25 mg/kg per five days/week for three weeks. Mice were euthanized by cervical dislocation, and organ biopsies (tibias and femurs) were collected from animals and fixed overnight in 10% neutral-buffered formalin (Sigma-Aldrich, #HT501128-4L). Tibias or vertebrae were incubated for 24 hr in Cal-Ex (Thermo Fisher Scientific, #C511-ID) to remove calcium residues and then dehydrated and preserved in 70% ethanol at ambient temperature. Fixed tissues were then embedded in paraffin following standard protocols. Leukemic cells were released from femurs and tibias by mechanic crushing in a solution of 2% FBS/PBS and filtered using 30- μ m pre-separation filters (Miltenyi Biotec, Bergisch Gladbach, Germany #130-041-407) prior to analysis of hCD45 by flow cytometry.

Statistical analysis

Statistical analyses were performed using GraphPad Prism 8 or R software. The means, standard deviation ($\pm$ SD), group size, experimental details, and statistical significance are described in the figure legends in the methods section. The assumption of normal distribution was not determined, and the *P* value among samples was calculated by parametric and non-parametric *t*-test. We used one- or two-way ANOVA using statistical correction for multiple comparison algorithms, as specified in the figure legends, to determine appropriate significance among groups.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Publicly available dataset used in this study are available at <https://www.ebi.ac.uk/biostudies/arrayexpress>, <https://www.ncbi.nlm.nih.gov/geo/>, or <https://www.cbiportal.org/> (E-GEOD 16238¹⁹, GSE14468³¹, GSE134589³², E-MTAB-2225¹⁵). Data generated in this study have been deposited in ProteomeXchange Consortium PRIDE repository under accession number PXD038686 (RIME mass spectrometry), NCBI's GEO repository under accession number GSE259221 (HNT34 RNA-seq), GSE220170 (MOLM1 and UCSD/AML1 RNA-seq), GSE256129 (HNT34 ChIP-seq), GSE256130 (PR#002 scRNA-seq), GSE256040 (PDLX_PR#003 scRNA-seq), GSE256076 (PDLX_PR#008 scRNA-seq). The raw FASTQ files from NGS DNA sequencing (Sophia "Myeloid solution" panel) are available under restricted access, due to Institutional policies and privacy laws for sensitive, genomic, and personal data, in the European Genome Archive (EGA) repository at EGAD50000000506. Access for non-commercial academic use can be

granted upon an email request to the lead contact (giovanni.r-oti@unipr.it) within two weeks and is contingent upon a Data Access Agreement between institutions. Data will be available for six month once access has been granted. The remaining data are available within the Article, Supplementary Information or Source Data File. Source data are provided with this paper.

References

- Bushweller, J. H. Targeting transcription factors in cancer—from undruggable to reality. *Nat Rev Cancer* **19**, 611–624 (2019).
- Henley, M. J. & Koehler, A. N. Advances in targeting ‘undruggable’ transcription factors with small molecules. *Nat Rev Drug Discov* **20**, 669–688 (2021).
- Morishita, K. et al. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300–400 kilobases on chromosome band 3q26. *Proc Natl Acad Sci USA* **89**, 3937–3941 (1992).
- Papaemmanuil, E. et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. *N Engl J Med* **374**, 2209–2221 (2016).
- Birdwell, C. et al. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies. *Blood Cancer J* **11**, 64 (2021).
- Lugthart, S. et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. *J Clin Oncol* **28**, 3890–3898 (2010).
- Cui, W., Sun, J., Cotta, C. V., Medeiros, L. J. & Lin, P. Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia. *Am J Clin Pathol* **136**, 282–288 (2011).
- Gröschel, S. et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. *J Clin Oncol* **28**, 2101–2107 (2010).
- Sun, J. et al. De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification. *Mod Pathol* **24**, 384–389 (2011).
- Lugthart, S. et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. *Blood* **111**, 4329–4337 (2008).
- Dombret, H. & Gardin, C. An update of current treatments for adult acute myeloid leukemia. *Blood* **127**, 53–61 (2016).
- Pintado, T., Ferro, M. T., San Román, C., Mayayo, M. & Laraña, J. G. Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. *Cancer* **55**, 535–541 (1985).
- Sitges, M. et al. Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols. *Eur J Haematol* **105**, 138–147 (2020).
- Halaburda, K. et al. Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Haematologica* **105**, 1723–1730 (2020).
- Gröschel, S. et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. *Cell* **157**, 369–381 (2014).
- Syed, J. et al. Targeted suppression of EVI1 oncogene expression by sequence-specific pyrrole-imidazole polyamide. *Chem Biol* **21**, 1370–1380 (2014).
- Fenouille, N. et al. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. *Nat Med* **23**, 301–313 (2017).
- Haferlach, C. et al. The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML. *Leukemia* **25**, 874–877 (2011).
- Vazquez, I. et al. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. *Haematologica* **96**, 1448–1456 (2011).
- Subramanian, A. et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. *Cell* **171**, 1437–1452.e1417 (2017).
- Wang, Z., Lachmann, A., Keenan, A. B. & Ma’ayan, A. L1000FWD: fireworks visualization of drug-induced transcriptomic signatures. *Bioinformatics* **34**, 2150–2152 (2018).
- Paredes, R. et al. EVI1 oncoprotein expression and CtBP1-association oscillate through the cell cycle. *Mol Biol Rep* **47**, 8293–8300 (2020).
- Lee, H. Z. et al. FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma. *Clin Cancer Res* **21**, 2666–2670 (2015).
- Prebet, T. et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. *J Clin Oncol* **32**, 1242–1248 (2014).
- Konrad, T. A. et al. Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes. *J Leukoc Biol* **86**, 813–822 (2009).
- Liverani, C. et al. Lineage-specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture. *Mol Oncol* **16**, 921–939 (2022).
- Lavallee, V. P. et al. EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations. *Blood* **125**, 140–143 (2015).
- Prebet, T. et al. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. *Br J Haematol* **172**, 384–391 (2016).
- Wang, J. et al. Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. *Target Oncol* **16**, 591–599 (2021).
- Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. *Nature* **462**, 108–112 (2009).
- Glass, C. et al. Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia. *PLoS One* **8**, e67134 (2013).
- Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukaemia. *Nature* **562**, 526–531 (2018).
- San Jose-Eneriz, E., Gimenez-Camino, N., Agirre, X. & Prosper, F. HDAC Inhibitors in Acute Myeloid Leukemia. *Cancers (Basel)* **11**, 1794 (2019).
- Andreatta, M. & Carmona, S. J. UCell: Robust and scalable single-cell gene signature scoring. *Comput Struct Biotechnol J* **19**, 3796–3798 (2021).
- Pei, Y. et al. HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. *Cancer Cell* **29**, 311–323 (2016).
- Winkler, R. et al. Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition. *Oncogene* **41**, 4560–4572 (2022).
- Topper, M. J. et al. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. *Cell* **171**, 1284–1300.e1221 (2017).
- Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. *Cell* **153**, 320–334 (2013).

39. Mohammed, H. et al. Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes. *Nat Protoc* **11**, 316–326 (2016).
40. Bard-Chapeau, E. A. et al. EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation. *Proc Natl Acad Sci USA* **110**, E2885–E2894 (2013).
41. Squatrito, M., Mancino, M., Donzelli, M., Areces, L. B. & Draetta, G. F. EBP1 is a nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes. *Oncogene* **23**, 4454–4465 (2004).
42. Liu, Z., Ahn, J. Y., Liu, X. & Ye, K. Ebp1 isoforms distinctively regulate cell survival and differentiation. *Proc Natl Acad Sci USA* **103**, 10917–10922 (2006).
43. Ko, H. R. et al. Roles of ErbB3-binding protein 1 (EBP1) in embryonic development and gene-silencing control. *Proc Natl Acad Sci USA* **116**, 24852–24860 (2019).
44. Koach, J. et al. Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface. *Cancer Res* **79**, 5652–5667 (2019).
45. Wouters, B. J. et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. *Blood* **113**, 3088–3091 (2009).
46. Vadakekolathu, J. et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. *Sci Transl Med* **12**, eaaz0463 (2020).
47. Shen, W. et al. Small-molecule inducer of β cell proliferation identified by high-throughput screening. *J Am Chem Soc* **135**, 1669–1672 (2013).
48. Kohl, N. E. et al. Human N-myc is closely related in organization and nucleotide sequence to c-myc. *Nature* **319**, 73–77 (1986).
49. Kim, E. S. Midostaurin: First Global Approval. *Drugs* **77**, 1251–1259 (2017).
50. Dhillon, S. Gilteritinib: First Global Approval. *Drugs* **79**, 331–339 (2019).
51. Yamaura, T. et al. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. *Blood* **131**, 426–438 (2018).
52. Dombret, H. et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. *Blood* **126**, 291–299 (2015).
53. Stein, E. M. et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. *Blood* **133**, 676–687 (2019).
54. Ravandi, F., Cortes, J. & Kantarjian, H. Is there a standard induction regimen for patients with AML? *Lancet Oncol* **14**, 565–566 (2013).
55. Stone, R. M. Consolidation chemotherapy for adults with AML in first remission: is there a best choice? *J Clin Oncol* **31**, 2067–2069 (2013).
56. Rashidi, A., Walter, R. B., Tallman, M. S., Appelbaum, F. R. & DiPersio, J. F. Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. *Blood* **128**, 763–773 (2016).
57. Reiter, E. et al. Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inv(3)(q21;q26) or homologous translocation t(3;3)(q21;q26). *Ann Hematol* **79**, 374–377 (2000).
58. Halaburda, K. et al. AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. *Bone Marrow Transplant* **53**, 683–691 (2018).
59. Zhang, L. et al. Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance. *Nat Commun* **12**, 6154 (2021).
60. Perkins, A. S. & Kim, J. H. Zinc fingers 1–7 of EVI1 fail to bind to the GATA motif by itself but require the core site GACAAGATA for binding. *J Biol Chem* **271**, 1104–1110 (1996).
61. Zhang, Y. et al. Targeting a DNA binding motif of the EVI1 protein by a pyrrole-imidazole polyamide. *Biochemistry* **50**, 10431–10441 (2011).
62. Kiehlmeier, S. et al. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia. *Leukemia* **35**, 3127–3138 (2021).
63. Morice, P. M. et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. *Lancet Haematol* **8**, e122–e134 (2021).
64. Vinatzer, U., Taplick, J., Seiser, C., Fonatsch, C. & Wieser, R. The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase. *Br J Haematol* **114**, 566–573 (2001).
65. Izutsu, K. et al. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. *Blood* **97**, 2815–2822 (2001).
66. Senyuk, V. et al. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells. *Oncogene* **21**, 3232–3240 (2002).
67. Chakraborty, S., Senyuk, V., Sitailo, S., Chi, Y. & Nucifora, G. Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles. *J Biol Chem* **276**, 44936–44943 (2001).
68. Gabay, M., Li, Y. & Felsher, D. W. MYC activation is a hallmark of cancer initiation and maintenance. *Cold Spring Harb Perspect Med* **4**, a014241 (2014).
69. Yun, S. et al. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). *Leuk Res* **84**, 106194 (2019).
70. Ohanian, M. et al. MYC protein expression is an important prognostic factor in acute myeloid leukemia. *Leuk Lymphoma* **60**, 37–48 (2019).
71. Mughal, M. K. et al. Acute myeloid leukaemia: expression of MYC protein and its association with cytogenetic risk profile and overall survival. *Hematol Oncol* **35**, 350–356 (2017).
72. Ottema, S. et al. The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops. *Nat Commun* **12**, 5679 (2021).
73. Bard-Chapeau, E. A. et al. Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors. *Proc Natl Acad Sci USA* **109**, 2168–2173 (2012).
74. Yatsula, B. et al. Identification of binding sites of EVI1 in mammalian cells. *J Biol Chem* **280**, 30712–30722 (2005).
75. Goyama, S. et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. *Cell Stem Cell* **3**, 207–220 (2008).
76. Yoshimi, A. et al. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. *Blood* **117**, 3617–3628 (2011).
77. Stevenson, B. W. et al. A structural view of PA2G4 isoforms with opposing functions in cancer. *J Biol Chem* **295**, 16100–16112 (2020).
78. Ko, H. R., Chang, Y. S., Park, W. S. & Ahn, J. Y. Opposing roles of the two isoforms of ErbB3 binding protein 1 in human cancer cells. *Int J Cancer* **139**, 1202–1208 (2016).
79. Kim, C. K. et al. Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. *Cancer Res* **70**, 9730–9741 (2010).

80. Kim, C. K. et al. Long isoform of ErbB3 binding protein, p48, mediates protein kinase B/Akt-dependent HDM2 stabilization and nuclear localization. *Exp Cell Res* **318**, 136–143 (2012).
81. Hwang, I., Ko, H. R. & Ahn, J. Y. The roles of multifunctional protein ErbB3 binding protein 1 (EBP1) isoforms from development to disease. *Exp Mol Med* **52**, 1039–1047 (2020).
82. Wang, Y. et al. Distinct Interactions of EBP1 Isoforms with FBXW7 Elicits Different Functions in Cancer. *Cancer Res* **77**, 1983–1996 (2017).
83. Nguyen le, X. T., Zhu, L., Lee, Y., Ta, L. & Mitchell, B. S. Expression and Role of the ErbB3-Binding Protein 1 in Acute Myelogenous Leukemic Cells. *Clin Cancer Res* **22**, 3320–3327 (2016).
84. Tang, Y. et al. Induced lineage promiscuity undermines the efficiency of all-trans-retinoid-acid-induced differentiation of acute myeloid leukemia. *iScience* **24**, 102410 (2021).
85. Chi, H. T. et al. Detection of exon 12 type A mutation of NPM1 gene in IMS-M2 cell line. *Leuk Res* **34**, 261–262 (2010).
86. Twarog, N. R., Stewart, E., Hammill, C. V. & Shelat, A. A. BRAID: A Unifying Paradigm for the Analysis of Combined Drug Action. *Sci Rep* **6**, 25523 (2016).
87. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. *Science* **313**, 1929–1935 (2006).
88. Pilarczyk, M. et al. Connecting omics signatures and revealing biological mechanisms with iLINCS. *Nat Commun* **13**, 4678 (2022).
89. Efron, B. Bootstrap methods: another look at the jackknife. In *Breakthroughs in statistics: Methodology and distribution*. Vol. II 569–593 (Springer, 1992).
90. Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. *Sci Rep* **7**, 16878 (2017).
91. Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. *Nat Biotechnol* **38**, 276–278 (2020).
92. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). *Genome Biol* **9**, R137 (2008).
93. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* **38**, 576–589 (2010).
94. Robinson, J. T. et al. Integrative genomics viewer. *Nat Biotechnol* **29**, 24–26 (2011).
95. Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. *Nat Biotechnol* **33**, 495–502 (2015).
96. Hao, Y. et al. Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587.e3529 (2021).

Acknowledgements

The project was supported by an AIRC Start-up Investigator Grant (no. 17107 to G.R.), Fondazione Cariparma (3576/2017 and 0180/2018 to G.R.), Fondazione Grande Ale Onlus (to G.R.), Leukemia Research Foundation (to G.R.), Fondazione GIMEMA (to G.R.), L'antica Torre di Mezzole (to M.M.), Beat-Leukemia SIES fellowship (to M.M.), Beat-Leukemia ONLUS (A.C.), Associazione Italiana contro le Leucemie-Linfomi e Mieloma, and ONLUS Parma chapter (to A.G. and G.R.) and MYNERVA project AIRC 5×1000 (to C.M. and M.P.M.). Chiara Robuschi and her family provided valuable support and inspiration throughout this work. The authors thank Enrico Maria Silini, M.D., Ph.D., for the technical support of the Pathology Department at the University of Parma, Prof. Rotraud Wieser Ph.D. from the Medical University of Vienna, who kindly shared with us the EVI1-inducible U937T model, Francesca Ruggieri and Giorgia Simonetti, Ph.D. for scRNASeq guidance, Pamela Criscuoli for administrative assistance, Roberto Ferrari, Ph.D. for ChIP-Seq

supervision, Monica Crugnola M.D., Amelia Rinaldi M.D., Lucia Prezioso M.D. Ph.D., for clinical oversight, and the physicians and nurses at the Hematology and BMT unit of the University of Parma. The authors are deeply grateful to the participant of this study. The authors thank Martin Neuenschwander, Ph.D. at the Leibniz Institute of Molecular Pharmacology and EU-OPENSOURCE Research Infrastructure Consortium (ERIC). The authors are grateful to Donna S. Neuberg, Sc.D., and Mary C. Dinanuer, M.D., Ph.D., and the 2018 EHA-ASH Translational Training in Hematology faculty and scholars. Authors thank Ann Sutton for scientific proofreading at the Editing Services, Research Medical Library at the The University of Texas MD Anderson Cancer Center. The authors thank Syndax Pharmaceuticals, Inc. for providing entinostat under a compassionate use program.

Author contributions

Conceptualization and Design, M.M., A.G., and G.R.; Methodology and Experiment Execution, A.G., E.S., M.M., A.M., N.T., F.V., C.L., E.S., A.D., C.C., C.S., A.F., V.A., B.L., F.M., A.M.L., and R.Z.; Samples Collection and Processing, E.F., B.C., G.S., L.P., M.G., G.T., S.B., A.G., E.S., E.C., A.C. M.P.M., R.L.S., and C.M.; Clinical care team, B.C., E.F., M.C., G.R., Formal Analysis L.M.D.T., S.P., A.M., C.C., M.M., and G.R.; Investigation, M.M., A.G., E.S., E.F., G.S., F.Q. and G.R.; Writing—Review & Editing, M.M., S.C., F.A., F.Q., and G.R.; Data Curation A.G., M.M., and G.R.; Supervision G.R.; All the authors read and discussed the manuscript.

Competing interests

The authors have no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-024-48953-3>.

Correspondence and requests for materials should be addressed to Giovanni Roti.

Peer review information *Nature Communications* thanks the anonymous reviewers for their contribution to the peer review of this work. A peer review file is available.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

¹Department of Medicine and Surgery, University of Parma, Parma, Italy. ²Translational Hematology and Chemogenomics Laboratory, University of Parma, Parma, Italy. ³IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy. ⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁵Department of Medical Science, University of Ferrara, Ferrara, Italy. ⁶Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy. ⁷Hematology and BMT Unit, Azienda USL Piacenza, Piacenza, Italy. ⁸High-Throughput Screening Core Facility, CIBIO, University of Trento, Trento, Italy. ⁹Computational Biology group, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy. ¹⁰University of Milano-Bicocca, Department of Medicine and Surgery, NANOMIB Center, Monza, Italy. ¹¹IRCCS Istituto Ortopedico Galeazzi, Milan, Italy. ¹²Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria Della Misericordia Hospital, Perugia, Italy. ¹³Hematology Unit, Azienda Ospedaliera-Universitaria S.ANNA, University of Ferrara, Ferrara, Italy. ¹⁴These authors contributed equally: Andrea Gherli, Elisa Simoncini, Lucas Moron Dalla Tor. ¹⁵Unaffiliated: Franco Aversa. ✉ e-mail: giovanni.roti@unipr.it